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1. M:dlcinal prod,rcts for veteri:rary use; like thoso for human therapyl are
gover.ncd W d.ifferent legal provisions from onc l{ember State to another.
The need. for community ru3-cs is obvious from the eoonomic point of v'icw.
Atthough the number of prcparations is d.istinctly smallcr than in hu'man
mcdicinc - the proportion may be aesesscd. at 1 to 10 - tho oonsumption of, andl
thcrcforc, the'tra'd'e in these pn'oparations are consi'd'erable' stock-r'aising
is bocoming more arrd morc ind.ustrialiaed. Th: concentration and' intcrnsification
of stock-raising which results from this and. the selection of higirl'y' productivc
brceds lncreasc thc risks of d.iseases and. thelr economic consequonccs' lfith
the a.chievement of thc common ag:ricul.turaL market, the objcctives oll prod'uctionl
profitability, freedom of rnovgment a,nd und.istorted. cornpetitlon have become
vital in this ficlcL'
Th,: neod. for rulcs is evcn more evid.ent from the standpoint of publllc heaLtht
l,Iith the growing consurnption of animal prod.ucts, it is osscntial thrrt the
consumer of thc treated. animal shouLd sirffer no ha^rm. At tlris timor when
probloms of quality aro again claiming atten'Lion1 it is hardly nccorrsary to
stross tho bencfit to health which rul"es in this field would- confer,'
2. This proposal for a d.irectlve is basccL on the princi'ple that thc rc'Tuipomcnts
laid. cl.orvn for v:;tcriurary mcd.icinal prod.uots shouLd. not be lcss stri:ngcnt than
those specified" for pharmaceutloal prod.ucts for human uee. This is in the
lnterests of consumers of prod.ucts of, animaL orig:in, ltho must suffer no harml
and also iir the intercsts of effective therapy.
,/.
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that is wlr"y, whcrever possibLe, tho trrrovlsi.ons eoncerning proprietarXr mcd.icinal
products for human use (f) have been taken apross to this fie1d., Ncverthclcss,
in ordbr to make aLlsi.ralxce for problcms peculiar to th; vcterina^rry fi':ld, it
was ncoessary to ad.d. certain special provisions.
3. The scope of the cl.ircctives ral.ating to human usc and that of this Directivc
d.o not coincid.eo Ths structr:res of tho two markets are d.iffer-ent. On the markets
of certain countries, vetcrinary' rned,icinal pr,od.ucts a.re commercializcd. in the
forrn of ready-mad.c med.icinal prod.ucts and not proprietary medicinal prod.uctst
in ord.or to keep d.or,n: the cost of packagingo For thc sarnc rcasons international
trad.o is'canicd. on ruainly in rearly-nad.u med.iciiral, products.
In ordor to includ.e most of the prod.ucts entoring into international" trade it
is therefore noccssary to wid.cn thc scopc of the Directivo. This is also
necessar1l for reasons of compctition, sinco th;'strict rcgulation of one
category of prod.ucts v;ould. cause prod.ucti.on to swing torrards other Less super-
visccl catogorics, arrd. this would ultimatc\y bc harmful to publio hea]-th.
Anothcr pcculiarity of vctcrinary med.icina.l prod.ucts is the d.angcr of rcsiducs
in animal prod.ucts. It must be borne in mind. that pcoplc may be harmed. by
ingesting prod.ucts dcrivod. from animals to which mod.icinal prod.ucts have bcen
adrninistcrcd.. This raiscs the questions of the p.:rsistencc of the medicinal
prod.uct, the routc a.nd- duration of eliminaticn, and the ncocssarlr wailing
period between uso of the med.iginal prod.uct ,:nd. eonsurnption of th': animal
prod.uct. This problcm of resid.ues on\r ariscs in the case of prod.ucts
a.dmini*tcred to animals whlch aro likely to provid.e l.Xan with food., Loss
stringent d.cmands might thcrefore havc becn expccted in th-- case of modLcinal
prOd.ucts administcrcd. to c,;rtain animeul spocics, petsl for instance. It ncvcr-
theless seemed. hazardrous to crcate two soparate catcg:orics of mcd.icinal
prod.ucts in vicw of thc corrupt aniL fraud.ulcnt practiccs which might havo
onsued. and thc problcms of supernrision which woultl. thon harre ariscn. It
appeared wlsar to allor.r certain waivers within thc framowork of thc standarcls
















Tho alm of thls work on the appro:cimation of
mcnt of. votorinalT rncilicina] prod'ucts wlriLo
pubLic hcalthr
Laws is to introdusc ftoe movo-
provid.lng cvery safog*ard. for
l
Ildvlng tal<en steps to safeguard public hcaLth. at tho prod''nct testingl manlr-
factur;ing *4 parlceting:'stagcl the n';rt problom which arosb was tha't of the
frcc movcmcnt of theso prod.ucts'
Tho intro&uctionl at this stago, of f,reod.om of, movcrncnt might ssem foasiblc
since tho position lritlr rogard. to vetorinarry mcd-icinol prod"ucts is not
id-entical with'tirat of mcd.icinal prod.ucts for human uEe. .Thc public hcalth
hazard.s n4y soom lcss serious, sinoc thc animaL is used. as an intarmcd'laqy
and. thcrcfore acts as a scricn bctuoen thc mcd.icinal produot and. I'Ian.
community rul"cs ad.optcd. for a€ricuLturc havo madc it posslblo to cnsure'
frccdom of rnovcment for egricuLtural produots wlrilc sccurirrg thc protcction
of public hcalth.
fhcse arguments wc:re not d.cvoicl of ucight 'out thoy clashcd. with c'thet *Ao1*"
concelning thc nccd. to progrcss by str,gos in a ficlcl. which is cLosc$ relatcd'
to hoaLth and. is of prim+ importanco for the econor0y of ce:r]ain oountries.
Ingtoa.d of wcighing up conflicting argumonts.nhich ccntributc not;h:ing toilalds
hcalgr and postponc frec movomcnt ind.cfinitcly, 'it appoar:d. prcfcrabl'e .to put
forward. mofc modcrato ploposals for introclucing, in the case of rtetcnina{V
mcd.icinal products, thc .systcm of movcmcnt al.roady adoptcil with r:ogard to ,
mccticine,l- prodlrcts for irularr uso. This should. onable thc pcriod.s for the
.adopti,on and lmpLemcntation of the texts to bo shortenod',and henco'malco. i.t
possi.ble to introduoe fr':o rnovernent for vetcrina'$r mcd'icinal proilucts morc'
rapid.ly.than ovar-anbitious proposals would all"ow.
./.
:4+
II. Commenta.::n on certai.n artieles
Arti-cle 1Fa:#
It goes without saying the,t the word tfanimall' refer-s to the whole of the
animal kingd.om and not mere\y to farrn aninals. New d.eflnitions to supplement
those in Councll Directive 65/65/WC are necessary as tho scope of the present
Iirective has been rvid.ened. to make alLowance for the special circrrinstances
which prevail in this Eector. Between the cl.omain of the medicinal product
d.efined by the Directive of 1965 a.nd that of add.itives in f,eed-ing*stuffst
d.ofined by Councit Directive No rc/V+ of 23 ldovenber 19?0 (0J t{o L 270 of
14 Decernber 19?0), there is a whole range of products that must be covered
b$ the :regulations'if manufacturers are to be prevented from evading the
requirements by marketing r.mder r:ncontrolled. forms.
Theregdiffersfromtheproprieta:ry
meiLiclnal prod.uct by the absence of a special narne (triviat name). It has
only a chemical narne or an international non-proprietary r!&[l€r Furthermoreg
it is not necessarily'offered f,or sale in a special pack but may be suppLied
ln bulk. It is specifiecl. that the ready-made product is narketad'in a
pharma,ceutical forrh which rnay be used. wlthout further processing and it is
therefore at this stage that authorization must be obtalned',for it'
The llg:gig for med.icated feetls is deflned, fr:ndarnentall-y by its pufpose: it ie
intendect fof ui.torior use'in a medicated. feed. This is how it is disrtiJgu-ished'
from the read*n*mad.e pnod.uct which may be' used. wlthout further processing and
is not intended. for this ulterior use. On the other hand'1 a pre-mix,is not








In contrast; the tnedicd,;d:Ise-+.'is a-mfrture ofi one'or'more meclic:inal
lr;i:rrations with one or more f,eed'ing*stuffsr ilade before marlceti:ng. Itr:?q
be used. fithout further pr.ocessing and this d.istingulsires it from the'iird-frilx.
Its therapeutic purpose d.r'fferdntiates it from the compowrd. foedi:ng-stirff.
.{lrticle 2 :
]; Apa4.t from the econo:nic goals-to be reachedr the qhief cor|cef;n was !.o, snsu]e
,that substances hafinful to lt{an.are'not admlnisterod to, him Via his,fqod..
A ned.icinal preparati6n is a product tiko3-y to be ,hazarclous an'&'must there-
' fcre be iad.e suiijdct to authorization trrespective of the way i4'wlrich. it
wi"ll be employed. subseguentlyo Aside from the economlc psngld.e.rationg ;;
alrea.tly mentioned., this is the reason which has led to the widoaing.'o! .,the
scope, of this nirectivo as compared" with tho proposod. d.irective on proprieta.lSr
ned"icinal substances fo:r human .llse. , !:.'.,. .,' , .1 .. ,,.r '. t, - .. ,.. '
2"'On the other handl the' provisio+s.of th.r.s Directive do not. ad.orluately,gover
i cef,tain specifio cases (sera and vaccines, med.icinal productq,'based,,on;'
rad.ioa,ctivc iootopes) ar-rd it is advisable not. to appty.tlrern to,these prducts
. , &t present. . ' j r ' ,r,. , . r . r
;
Similarly, it was not consid.ered. advisable to mal<e these provisi.ons
in the case of prod.uots which carr have no effect. on fntra;Co44'uniiy
naraeLyr veterinary medicinaL prod.ucts not prepared in advancel ,thi9,
to med.i.cinal prod.ucts which corresponcl to tlrugs pTepare0 accorrlting
presoription in. human meclicine, i.e. med.icinal pr.oducts preper'ad' by
vetdrinari.an foir one particuLar a.raimaL, foll,ruring dia€nosiq:r , , ..
Final\y, i"n order to make the preoent nrles effective; it bas 'been oecii"*ar;,
to regulate one aspect of the manufacture of rned.icateil feed.ing.-stuffs











,aragraph L of this ArticLe is t*ho1ly eornparable to the provisions governing
r proprietarXr mecl,icinal prod,ucts for human use.
para€raph 2 has been rnad.e necessarlr by the special situation which could' arise
in this sector;for a trparallelil market, subject to no supervieion whatso€v€T;
rnight em6rge if the nrle simple statecl. that any medicilal product placod on
tho rnarket must be subject to prior authorlzation. It would. be possibLe to get
ror:nd. the rules. fhe firgt step wouLd. be to procurer as a raw materiaL, such
an6 suoh a, substance fon which no prophylaptic or curative prop€rtiee are
clalmccl; no authorization woulcl be necessa.ry since it woulcL be a raw material
and not a moclicinaL substanoe. Tbereaf,ter, the ptrchaeor would employ this
eubEtance as medication f,or his onrn livestock; no authorization vrould' be
necessarlr since this med.icinal product woulcl not bave been placed' on the
market a"s such' 
*rr rrmr.ti rra rrnar ro oolnt of view of both public$uch a possibility vrorlcl be rma,cceptable from th p
health and. the econonY.
It has therefore been aecessarJr to go beyond, the iclea of marketing ancl' to
lqy cLoltn an qngqalifiect prohibition of a.dmj-aistration to an animal of a
rneal.iOinal product, in any fo:rn whatso€vert which has not been authorized
pr*suant to the provisions of this Directive. This provision assumos its fuLl
meariing if reference is made to the ooncept of a moclicinaL product as lald
d.own in Articte 1(a) or Councll Direotive Wo 6S16S of 26 January 1965.
It is very certai-n tbat Euoh a pl|ovision gil'Bs riee to dlifficult probLems of
supervisiolri At the smbrtinel however, publlc authorlties must be abl-e to
counter the cornrpt praottcee which corllit stem firom the purchaso of substances
not subject to 
.the Directivers plsovisl'one anel 
yet empl'oyed' for a therapeutic
ptr'poser If such practioes are discovercd. they must be penalizecl'; thie justifies
such a provision even lf it i.s dtfficul"t to implemont iti
Arr exceptlon must be mad.e in ordler to alLow teets to be carried' out on meclicinal





The tbe:rapeutic inclicatlons nugt be taken ln a broad soneei the rrt;herapeutio
effectfr concept must be under.stood to bo thE effect prornisetl. by the nanu-
fapturor. $utatis mrtand,isl the therapeutlo ind.ications cover the inclicatione
quoted. f,or med.iclnal proclucts alleged. to possess curatlve or prop]yla,otic
propertles ancl aLso thoso quotetl for rned.ictnal producte intenaled llor rnaking
a med,ical diagnosis or reetoring; oorrectlng or modl.tfying pttysiological
firnctiong in aninals. :
raragrgn! f
[he phrase Itdogage for the various aalmat speci,es for whioh the merdicinal
product is intendecl mrst be inteqpretecl with oornrnon sense: lf a clj.ff,enent
cl,oee has to be administerecl to calves, coldsr heifers etc.l the d.osage ntrst
of course bc given for these sub-categories.
Paraeryp! I
The person responsible for plaaing tho proctuct on the ma.rket rmrst.provid.e
alL necossarly lnformation coacerning the precautlons to be taken cl.r:ring use
of the product in ord.or to ensuro the sa,fety of the person adninistering lt.
Article 10
1t may be forbidd.on W lar to uge certa.ln eubgtances for particulelr purposes;
an exarnp!,e is tbc use of oestrogpns to fatten cattle. But if thesel subgtancos
exert a therapcutic effect, they rnrst be allouect to quatlfy for arrthorizatton
ag meiticlnal products. In orden to :reconolle theee requlremsnts; tuthorizatior
rnay be nofueecl lf the rnocllcinal, product ls offsred. for salel for a. use
prohibitect r:nder other cqrffnunity provLslons (paracraph 3). on the other halrdl






1. In order to allow tbe marketirlg of med,icinal products whioh a"rs useful but
which also preeent dlofinlte hazards, tho authorizatlon may entail the
obligation to print the necessaty walnings on the Label ancl the package
insert. The reference to clinical and pharmacologlcal trlals is designecl
to confer an objectivo chara,cter on this provision. The second paragraph
of Artiale 13 enableg the authorities to take a,ccor:nt'of iteros of
information which energe a^f,ter the med.icinal prod.uct ie marketecl and t0
recousider tbe neocl. to make sarnings obligatory.
A. At presont tho question of, traoer substances does not apPeaf important
enough to require a study at Connnunity 1eve3. of all tracer eubstancee and
of all medicinal produots which snrst be tagged,. NeuertheLess it uould, be
desirable for }lember States not to npecif,f cl,ifferent tracer substances'
If joint cousultatlon provecl r:nsatiEfactory and if this problem were to
barnper freed.our of movomentl approximation nnca,sures would. then bo necessary.
In a3y event, tb,e nanufapturer shoul-ct be informecl about the obligation to
i' omploy a tracer substance before anct not a,fter he dotermiaes the formula
of his medictnal Product.
Article 13
Shls Articls makeg lt incumbont
proctuct on the marlcet to nod'ifY
testlng may result therefrorn.
on the person responsibLs for plaoing the
hls testlng: method's tf arr improvement in
It also makes it inournbent otr hln to notlfY the conrpntont au*ho:rities of any
new f,actore lrbich appoaa aftar the grant of narketing authorlzatioa;
- 
rrell faptors over whlch the p€rson rospongible for marketing has no







any new faptors whloh result frorn its use: mod.lficatlons l:n the
compositionl ctosagel tndioations eto. (tf*rA pa.ra€rapb), Naturally, ln a9cordance .
with the provislons of tho Dtroctiver ho wiLL have to give the reasons f,or
these $roposed charges.
It diil not appeap to be necessarJr to epeoify the obligations of tho oompotent
authorlties; they follow from the provisione of the Directive. The lnvestigation
mea.sures vrhich they will be led to take witl cLepond. on the new factors
corununlcatcd by the porson responslble andp in apcordance with the national
regulations, they wiII be led either to grant frosh authorization or to a€fee
to the mod.ifioatlon slmp\y W a letter to the pereon regponslb1e,
ry&is.
fn rogard to the Committeo for Veterinary Med,icinal Products it is proposetl to
apply provi.sions basecl. on thoes specifieat for the Comrnlttee for Proprietary
Mecl.icinal Proclucts ln Chapter finf of Direct*ve 75/3L9/W, for the reasons
put forttard in the General Considelrations.
Article 23
It is proposect to apply all the provLsions concernlng manufa,cture ancl irnport
from third countries, contalned in Directivo ]>/Stg/W; to voterina.qp
rnedlicinal products, Moreovor, lt shoulcl bc noted. that veterina,qf 'nred,lcine
appears among the ecientlf,lo d,isciplino l.ieted i,n A:rttcLe 23 of Di,r'eotive .
ll/Ztg/W* an article whl.ch laye d.own the mlnimurn Eralifioatlons requlrect
of persons who assume responsibiltty for ths manuf,acturs and. toeti.rg controls











The expiration d.ate has been nado rnandator-1r iri alL caeos in ordef 'to ensure the
corrcct use of medlcinal proclucts ancl to avoid, wastage which may be caused by
tho abgencs of this item of information. In ord.er not to givc the user an
wrgusti,fied, feeLing of security when the ned.icinaL produotl althor:gh not out-
clated.; may have d.eoonposecl. owing to ba.d. stora6:ereonditions, the nr:xt para€traph




In particularl this conoerns capsules on which it would. be d.ifficult to print
evon tho lorler
Arti.c,le 39.
tfe paAkage insert nflrst, wlthout erceptl,onl be incl.udect in the paokago of the
veterina,ry n:dlicinal product for the purpose of, information antl the corroct use
of the prod.uct. For exa,mplo, the fa^rmer must be informod concerning the
significanco of the waiting period. .4, certaitr numbor of items are needed so
that ths pa,ckage insert may fuLf11 this object and these iteme must correepond
to the inf,ormation ard' d'ocu'sronte suppl'ied' pursuant to article 4 arra verifiod
by the compotont authoritlas in a,cconlarroe with Article 10.
On the othor hand., the packg6o lnsert nnrgt not contal4 any advertisittg matterl
it muet concern so1ery the rnettLcinal proituct which it accompaniesi In the
interests of econonly, this d.oes not preclud.e mentioning the various forms of
thls neticlnaL product on one and the eame packago insert.
SimilarlV, tho narne of anotber nedicinal product may bo lncluded on it if the
rnarketing authorization presoribes euch a rsforence pursuant to the first








Inetnrctions for conrect ad.oinletration are neces$ary when tbe rnedlclnal
proclucts are completely effective only in certain fr:nctlonal stateg of . t-hg. t
organism (,:.g, when fastlng) or in oertaln stages of the d.isoase (e.g.
treatment of, parasitoses) or in aombination wlth celtain conconitant mcaerrroe .






tH$ couNclt oF glIE EtiRoPEAl[ CoITMUNTIISS,
Having rogard tq the Troaty esta.blisirlng the E\ropcan Economio Community,
and. in pa:rticular ,Articb L00 thereof '1
Having rega.rd. to the proposal from the Commission t
Havilg regartl to the opinion of the E\:ropoan Parlianent,
Harring rcgard to the Qplnion of the Economic ancl' Social Commi'tteet
Whersa,s the primarly purpose of any nrl,es f,or the..pforkc*.L'rm ard
cllstrlbution of voterl.narXy meclicinal products must bc thc r*;';6;r:an$ag of publlo
health;
lJhereass howeven, this objective must be achliwcd by means which will not
hincler the developmcnt of inclustry ald, tradc in mecl.ieinal products wit'hin the
Commwrity;
WheroaB, lnsofar as tho ldeufbor States aLrcady have certain provisions Laicl dLotrn
r by law, reg;rrlation or d.dsrinlstrative action gloverning veterina,ry medicinal
trrrodgcts, such provisions ctiffer Ju crrgo:r'lr1rr.!.l:r:t1i lt*iplib*;i8i.C';;i?irii?"oas birls
pcouits.,in tha ir{i*idering gf tr+clc ia;nea-i.sita;ii prvitr-.cts .tdiir,-.i'r1 il.6
6ommunity ancl thorery directly a^ffec€ thc establish,rcent and functioning of
thc coinmon markot;
wheroas such hind.rances rnrst apeord,irrgls be removsdS urd whereas this enta'iLs
approximati.on of the roLovant provisions;
l{hereas the provisions of thie DircctLve whlch conccrn voterina.lry rnecl'icinal
products are not actoquatel aLthough appropriatc, for vsterina$I rnedicinal
prod.ucts usoct..to confqr active irnmrrnityl to d'iagnoso tbe state of imrnuntty
and. to confer passivc immunity and for med.icinal produc*s basod' on raaioa'ctive
isotopes; whereas lt is therofore advisable not to prescribe their appl-ication
to such proclucts f,or tho P:resentl
./.
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t{hereas ned.lcatecl. feed.ing*ttuffs clo not come within the qmbit of, t.ble Dhootivet
but whereas it ls necessalyy as Ertob for pirbllo hcalth.as otrqrmlo loaaonei to . '
prohibit the uec of una,lrtlrorlzedl medticinal products in the manrrfacture of
med.icatecl feedingrstuffs; d
Whereas marketlng authorization shalX be refusedl where a med.icinal product
lacks therapeutic effect of where tbere is insufficient proof of euch effect
prornised. by the ma.nufacturersl
Ihereas it is ad.visgblel ia ord.er gradually to achieve freedom of movement by
veterinary med.icinal prod.ucts, to faciLitate the gfa,ntffrg of na,rk:ting-bdtlddEaF
tions in s.everal ldember $tatos for one and tbe sane medicinal producti
i{hereasr for this purpoeol a Committee for Veterina.ry Med.iclnal" Proclucts should'
be set upl conponod, rf representttives of the I'tembsr States and, of the
Commlssion, f,esponsible for gLving an opinion as to whether a particular
veterinarlr rned.icinal prod.uct complJ.es with the requirements get out irn this
Dlrectiv:1
Uhereas thisDirective is only one stage in the a.chievsment of the alrn of
froed,om of movoment ot voterina,ry med.icinal productsl whereaar fon this purpose,
new measures wiJ.L prove necessarJr, in the light of 
€lryortorbc gagud i: '.-r
especially within tho sa^id. Committeel f,or thc ronorra"l- of t\e
remaining bamiers to freed,om of movement l
Shercas, tn oz'de:r to facllitato the novenerrt of veter{.naqf msd,lotnal p}ocluotE
e{d, to prevent tho oheoks oarriedl. out ln one I'tember State frm beilng repeatcd
ln anotherl ninimr.u reguir,rnonts for nanr.rfactrre and lnports frm thild.
oourrtr'ies ancl the grant of authori.zatloa rel.atln6l thereto, Ehould, ibe applieilt
' to rretcri-:ra:ry neiLicinaL prodr:ots, aa Bpeclfi.ed in Counoil Directlvo
?l/l tgr&i0 on the app:roxJ.nation of provislolre laidt d.orn by lan, rel3ulatlon or
ailni.nietlative aotlon rcIating to proprietary ne&lainal p.roduatsr
EA*S ADOHIED mIS DIREdI'WE r
i itli
, . s.r.




1. the d-efinitions laid. d.or'rn in Articte .'l- of Counci! Directivc llo 65/61
*rr ili1rJ opetre*{:.ratlon <rf -pfov*cions tai.f rLc67u-bjr. }r*ri ,.-- -- ''' i '.-;
rogul"ation or a.d,ministrativc action r':lating to propriotary nnedicinal
/r \products\-/ shall appl"," to this lircctive.
2. Furtlermofe, for the pluposss of this Directive, thc foLlcr'd:lg ''icfinittons ehell
;rppLy
- 
vctcr1n{:u-?, :rcd,LoinnL produrrt nhal,i:i:e&&;&il},t-na*ioin*&carUdrrat' ilttendccl f,or
animalst
- Sga,4y:q;dl .ro3,eri,J}ary ggjEtn'3l-glqglq!. gltfi3.} nctrx.'c.t[n:trotr:]{:r"ady':ra4loinaL
product prepared. in a.d,va:rce and- nar]:eted. in a pharmaceutieal f'orm trhich
may be used. witirout further processing;
- prt,tl*gg-JEqtgg*sg&9gig#'t.uf.fq gba.t}. nc,4r.u.iri5r,.{rateei:ra$y-:r:r:{lclnal
prod.uct prepareC. in ad.vance vrith a vier'r to thc s"'rbsoguent' manr:fact-ore
of nsdicatcd. fccd.ing-stuffs t
*ry9i*.:JsgJs,g4jeesj€rn!*1.11'e;.1canatty,ri;ttuf<;.'of.r,.rct.griid.4fn,':J{"tlin*1
product or pfod.ucts and. fccd or feed.s wliich is rcady prcpare; for
lprtt*;tinfii e*r,.L lnt.ruC,urL to b* feii to e.lri.:.ral.;: r.rith':ut furthcr proclroingl
lrncau$o of ris o'lrniivo 6i:prpnortttve 'pi"oparl:'tr'b'r o'rhcrcpropartico
of the ned.isinal substance covered by Article f (e) of the aeiil
Council Directivorr r'.. ,'
3. Tho a,C.ditives incorporatecl. in animaL fced.ing-stuffs and the supple,nentarJr
animal feerling'-stuffs covered. by cor:nci1 Directivc No 7A/524 " ' ..:l- (c\
concerning ad.d.itives ln feed.ing-stuffs\'/ sha1l, for the purposes of
the present Direotivo, not bo consid.cred as med.icinal prod'ucts.
lgl'":9.-a
I. Thc provisione of, this Direc*'ivs shall applJ to veterinary rned'icinal prod.ucts
. i i' :;':;
(r) oi No 22 of g.2,Lg6it ?o zo
(e) 
o.l No L 2?o of r-4, Lz,rglo ..,ir ,/,
*L5_
:.r,iir-:tlior offcr:d for sale in the form of proprietarry mcd'icinal prod'.rtst
re:dy-raode vcterina^rTr mod.ioinal prod"ucts or pre-mixes
2. The pnovisions of this Dlrcctive shalL not appLy to:
( a) med.icated. feoiling-stuffs,
(b) voterinaqy modicinal products usecl. lrith a vicw to prod.ucing activc
immunity, d.iagnosing thc stato of immu:rity and producing pass:Lvc
i:nm:nity,r,
(c) veterina^ry med,icfnal prod.ucts based on rad.ioactive lsotopest
(d) veter.inary'medicinal prod.ucte not prepared in advance and intend.ed
for one particular animal.
3. Howeverl pending Separato proviEions for medicated. feoding-stttffsp a
p,re*mix shaLl uot'..bo usod, for thul;T:rgnufaoturo ,:f, r.rocl-lcntcci f,ooc'l.ind1*otuffc
if it has not roceivod, the authorization referrod to in Article 3,,
Chaptcr fI 
- 
Application for m.:rttctins authorizatien
f Qn y.q.t crr:l*qFv mc*i.c iTj' l .pXod qct fl
Articlo_ 3
1. 
-?l vcterinary ined.icinal lxoduct shall, not bo ;rarjretod in a: c:rbcr $t*t.: i.f
authonization iras not"irbcn pruvious\r issued. by thu cbrap.rt;nt autjrorl'Ly
of that liemb,:r Sratc.
2. X vcterlnary meilicinal product olrall not bc .e"ct"rtuistercct to anlr.rolo if 'bii,.;
authorization provided. for in the preceding para€raph has not beetrlissued.l
,:xcept lrherc tcsts of meti.icinal products refenrod. to in Article 4 {fO)
aro conccrncd.
$rtt"lg $
For thc p,rrposa of obtaining thc narkotlag authorization prorrid.eel. for in
Article 31 thc peroon ncsponstble fcr pLacing thc prcdrrct on tho rnarket




The folLowing particulars anrl d.ocurnr.rnts shalL bc appended to thic appl icaticn:
1 fio;no or corperate:rarae anC clonj.cj:ic or Bcrr:anoat..si"ibcss of thc FQlsou ]cspon-:ri:;1r:r:1-";"
p1acing thc mcd.icinal p::od.rict on thc market ancl-, t'rhcrc applicabletof tho
mairuf.rctr-irer' also I
2. narne of th,: mcd.icinal pr-od.uct (triviat narner ccilnnon namer with or without
a. trade mark or neu.,te of thc manufactuferl scientific nane or for;nula,
with or i,rithout a trade mark or name of the i'aanufacturer) I
3. r{ualitativs and. guahtitl,tivc particulars of all t}rc cornponcnts of the
mcd.ic.inal produc' o*gRossed. in,the rxstraL'ternsl'but eroluding cnpirical'chenica[
formulao, witir -ncntion of the internsrtional non-proprictary na:rc r.e-
' comrnendcd. by the l,forld Hcalth Olganization ,'if such ira$c existsl
4. bri.ef d.escription of tho method. of preparation;
5. therapcutic ind"ica"bions, contra*ind.ications and' siCe-effootsl
6. &osrgc for thc various specias of a:rineil for which thc'neClcinal'prod':'ot is
intend.cd., 1ts phntnaccuticaL f,or.ere ncthod ancl naans 'sft sinJ.nistration anil'
cxpcct;d. sirclf lifc; ' 
-
?r re&soos for the prccautiona^r1r a:rd. safety ineasurcs to ba taken whon using
the medicinal product, if applicable;
B. indication of th: ncccssaflr dcl.ay be*woen tho adBfnlstr{}ti'.on of :1 "
the med.icinaL prod.uct to animals und.er normal crnd.itions of usc and tho
production of food. stuffs fron such anlrial.si ln ordoilto onzurc'that such food'
. 
does not contain'any rosidues which $ight jeopard.iac the heal-tlr, of the
consumcr;
" ;:!f -
?. Dcrcrtption of tha tcsting methods ompLoyed. by the manufacturor (qualitatlve
*
and 
.q'uantitativc er^nalysis of the components and. the finished. prod.uctr spociaL
.l teet's' o.g. stcrility'tcsts, tests fbr thc prcsonce of pyrogenlo substancest
' for'thc prascnce of hcary meto.ls, bioLogica,l and. toxicity tcsts, tosts on
intermod.ia': e proiluct s) ;
10. Results of:
- 
plqrsicochemlcall biological or microblolog"ical tests;
- 




tlhe resuLts of thc toxicoLogical end phennacoLogical tcsts shalL r.-'late morc
particula.rly to the nretalolism of the ective cornponents irr the animal arrd tn par4t""l
oula4. to thc nod,e and. d.iua*ion of thcir olii:rinationl if such dCI,ta arc
important for the purpcsc of chooking tho'ind[lcatod rlolayl :'
Notwithstancling th-ir' f oregoingl
a) a.list of pubLished rcfcrences rcLatlng' to tho toxicoLogical a,ndl r
pharniacoS.ogical tcsts th$ alinical triaisrand the d.ata concerning
the dclay shal.l bo substltutod for tho rolcvan't toet rceults
in thc caso ofr
i) a nreclicinal product with an eBtablishcd use, whicb has beon
adeguately tostsd on animals so that its effcctsr i:nolucling
sid.c*,iffclcts, arc aLrcady lcrown and are includ.ed. in thc published,
r;fcr.lnces;
ii) a ncw msd.icinaL prod.uct, in which the active'
componcnts arc ld.ontieal to thoecof a laiou:r med.ici:naI product
with an estabLished. use;
iii) a new med.ioinal prod.uot containlng only lqxown compo:nents that
have already been used. toge*her '' in comparable proportions




b) in the case of a new med.iclnal procluct containi.:rg lcncln conponi:nts
not hithcrto usec 
-togp.thcs for thcrepc,rtic purrro,::s,
rcferexlcrs to publish:d. tl-atasha:.l bo sribs-hi,tutccl fon thc bcsts
. of such cctrtponrbntsl
I1e one or more specimcns or mock-ups of th,J sales prcse:rtation of tho
mcdicinaL prod.uct togcthcr r^rith a pa,ci;ago inserti
L2. a, d.ocumcnt sholrin6 that ttre manufa,cturcr is authorizod. in iris otrn countrTr
to prod.uce medicinal Productsl
13. arry authorize.tion to plaoe thc.rilorrant nc&icin8t:'prbdhbt on t'hs na'rlnvtt
whieh iray harrc bccn'otrbai.rrcd.iin another Iteirbel S+eto or in a thircl ccnrntry6
Articlc 5#
!.{ember States shal.l make all necessa.r}' a,rrangemcnts *o €!}sll?c, thel't; t}rsi.d'mnnpt*s
aud partj.culars l,:i,ste6" in potats Bn9 ana SOr of 
"hc.second. 
para#f$ of Ar'$icl'e c?.n'?e
drafted. by experts with tha; requlsite tocirnicaL or professional
qualifications before bcing submitted. to the compotent authorities.
These d.ocuinents and particulars shaLl bc signed. by the experts.
A"t"!ele I
According to their pariicular qualifications, tire rble of thc experts shall be:
I. to cagy out such trork as falLs wrthin' their particular d.isciplinc
(analysisl pharrnlcology- a:rd. slrcilar expcrimental scicnccst cl-inic3r'l




2, "io d.cscrrbe 'their findings in accordance r'rith Council Direptlve of .... r. '
pn the approxi;nation of the Laws of liember $tates roLating to e.na\rtical,
pharnraco*toxico!.oglcaL and cLinical stan<lard.s and protocols in respect of I
the tosting of vctcrinrxlr mcd.icinal prod.ucts, and in particuLar to state;
a) in the casc of enalysts, whether the prod.uct corrforr:s wlth i;hc
stated. compooiticq providtng ar$r reesone for tho testing mcthod.s
which the manufactrrer n&y ose i
f) i.n the case of 1fra'rnaadlogC.str crc sinilaf,ly quaLified. speclalistsr 
.
tho i;oxioity of, the proclrrct and tho phanraoolog!.cal
'properties obscrved,
- 
rthetherl a,ftor administ:ration of the med.icinal prod.uct und.,:r nonnal'
cond.itlons of, use and observance of the prescribed 11olay, food,
etu*gs. obtained from the treated. anirnals contain. residues which mighj
oonstitute a hEalth hazarrl to thc ooricrune?t
c*. in the casc of cliniciane, nhether tirey have found. efltccts lrr arrlnals tr.eated
with the product correspond,ing to the information fir:rnislred by
tho manufecturer irursuant to Article {1 whethcr the product :Ls well
tolerated.; l"hat dosage they necommcnd, and. What are tho cotrtra-lnd,ications
and. sid.c-effects, if ary;
3. to give rcasons for thc use of thc refcrenccs to publishcd. dat;r rcfcrrcd.
to in pmorisos a) a,nd, t) of ttcn 10 in {ha gccoald peragraph of Artialo draocordJ.ng
to the cond.itions Laid tlown \r Council Directive of .. r r r. I I on the
approxfrmation of tho Laws of i'Iember States relating to analytioall
pharmaco-toxicoLogical and. clinicat stand.ar"d.s and pr.otocols in respect






the expertst detai.lod. reports shall fo:m pa,ft of the ciosslilr l';l'rich tlu
applicant cha1l lodgc ;';itir the conpctcnt a"rtiroritios'






Ideniber States shal.l talce aLl appropriato measures to ensqrc that the prooed'ure
for grapting authoriaation to p]-ace a ve-berinary medicinal prod'uct on the
market is completed r+itirin L20 d.ays fron tho cla,be cf suh-rissl'on'of thq appLicationo
In exceptional cascs this time-Limit shall bo eciccxded'for a firrtlrer 9O daye.
the app}icant sha1l be notlfieC of such ortension before the expiry of the
initial time-liraito
gqticj-,e 3
In ord.er to examiae the application subrnitted- pursuent to Articlc 41 tho
competent autho:ities of the }iembor Statos shal-L :
check that the particulsrs sul-'nitted. in support of tlre application
complyr'iiththesaid.Artlclc4andeon*irebasisofthereportsd'::a;'rnup
by tlre crperts pursuant to Jlrticle 6, ascertain whr:ther thc condiiions for
the issue of the marlcoting authorization have becn fulfilled;
submj.t the rnc.Licinal pr"oduct for tosting by a State laboratory or a
laborertory d.eslgnated. for this purposo, in oacler to ensule ther"l the tcsting
mct|od,s of control cmployed. by the rnanufactr:rcr and' d.csc-rribed- in tho
d'ossier, in accord.ance with !tc"': 9 of the Eooond"pc;rag;'ai'ii of rlrticic $rare
satisfactory;
whcrc appropriatey rog',riro ' the a1:pl-icant to supplement the
dossicr as rcgards the iterns Listcd. in Article 4. lrlhere thc cor:pctent







in .LrticL: J,shall b': d.cferred. until tho euppter:ontoly.dryta-aaqrrtrned. hatre
ur;.rit provid.;d.. Sirlilarl+i these timo-Limits shalL bo d'cferrcd. for tho
pcriod. allowad to the appLicant, where appropriatel to explai:n himself
orally or in writing.
Articlo g
-
ltember States sha].L take all appropriate mcaslfres in ord.er tha*:
li 'the competent authorities rnay ascertain that the .manufacturers and. itnporters
of veterina.ry medicinal prod,ucto f,ron third. countries are ablc to carry
out manufaatwo in compliance with th,: clctaiLs supplied. pursuant to ttoi: 4 of ;
tlc geconn paragraph of Artlole 4 an/or to carrXr out the tests 1'n accorclancs
l,r'ith thc ncth,ods doscrlbcd. in fho d.ossiotr {rr}der ltcn ! of the soGond paraeraph
of, Article 4 l
2, thc conpotent authorities may authoriza nanufe.ctulers and inrportcrs of
vcterinarXr med.icinal prod.ucts from third corurtries, in exceptionaL" and'
justtficd. oases, to havo certain sta4cs of ma4itrf,acturl ard/or certain of
the tests reforrcd. to in para€raph I carriciL out by third partiosl in
euch casss tho tnvr:stigations $r thc competent authoritios shalL also
'ue oamied but in thoss cstabtrish'rcntd.
Artiglo L9
the authorization provid.ed for in Articlc 3 shaLl bo withheLd ifr a.ftcr
exainiuation of the docum':nts and' par4iculars llstcd' in Articlo 4r it appearsl
L. that thc med.icinal prod-uct is harmful as :rcgards thc. gonditl,otls of trse statodl at
thc tlnc c,f appltcat:lon for au'i;borlzationl or that thers ls rro thcrspoutic off.:cb
' tnBufftclont proof thorcof by the applioani as regnnd.s the epec,ics:of hnir:al
whlch ls to be trcated.s or that the grral.itatlve o" q,r*tftatlv'ir conrposition




2' tirat tirc waiting pcf iod' recomrcnd.cd, by ilrc appLicant is not long onoughto etrsure that food'stuffs obtaln.:d. frorn the treated. anirnar c.o not contalnresiducs.r";hich might jeopa,fdizc the hsalth c
' , ins.ufficiently substantiated. 
rf the co''sumcrl or is
3' that the ned'icinar product is offercd for sale for a uso pnohibitod, underoth.cr Comrrnlrity prorrisions.




raguirc . tho persgn responsibr.e for pracing the vete:ri";
med'ici:rar product on the market *bi indlsabo on ttre conta i,nar ana,/or theoutside' i'rpapping and' the packa€e insert other particulars essential for saf,etyor boaltb p:noteotioil r incr*ding arqr spccial prec.rutions relatirrg to "use and argr otiier warnings reeirltiug. fron:thc clibi,cal-bnd,pharm,ool.og661-..1.trials specifiecL in !.toqr::l0 of, Altiqls.4r:obf,rm expcl,ioacocgplned_.:durinB:th€
use of tho med'icinaL product oncc it has boen mariceted..
Authonization shall alEo req*lre the. tnclugton.of .a trs0cr
substance in thc rned.icinaL pnofluct.
Authorization shall also bo
authorities d.ocs not comply
lqtiple,.LL
Article 12
Ihe gmfitiag of .autborlaottbn ebatl aot
manufacturer and.l where appropriater of
the veterina,ry modicinaL product on ilre
wlti*rer'cr if the d.ossicr submlttod, to tho compotent
with ArticJ.es d' 5 and. 6.
4rtlcle l.J
The person rosponsibl.e for marketing slall aooa;rtfor in lten p'of afttole {in aecorrlance wtth tho
ard the progress of science if such adaptatloar
testing of thc mod,lcinal product.
dtntatbb the legel-labitity of the
tho p6rson responsible for placing
narkdt.








The porson rosponslbls for pLa,cing tho 
vetorinary med'icinal T"*-il 
-::, 
-::
market shall forthuith lnforln ' the competont 
authoqitios of airy new
information which entaiLs anlndnbnt 
of the nalicura'rs and d'lcuments roferrecl
toinArtl,clc4ora'dd'ltionalexaminationlan&'m6rc'ospeciallyar51p::ohibition
or restriction proscribocl by the compotent 
authoritics of'the stat s 'in uhich
the meclloinal' pf,ocluct is ma'rlceted' 
luct on thc
Ehe person rcsponsible for p1a'cing the wtorinarxf 
meitloinal pru
markot sha'l fmmediatery inf,orm tho 




Authori zar ion shatrl be valrct- t":, :t::,i::: il:"'T:t;:"1"*T?J r;;;J,;4e+-v- t: ' 
- bhe holcl'er withia tbe three oorlTne 1year poriotls, on application']ry 
--.rr.,^ *'a n.a*tgiong of artlole 130
;;;; esptqr, J.n aooordanroe wtth the 
prevlsi s
chlilcter. r\I. - cg,Fnrtte.e .fo,f, rqtcr.i.+arv., Jlp*iFinpl 
Frod,*cte I
rosltion' bY ther I'lember
In oniter to fa,cilltate the adopt'ion of a corunon 1
states drth*eeprit:-to eor'lmli'{raiBpt&ofi'ea}i'ons' ?', 
cTtItT-.t:: 
:teriTr}'rt da* Iln!
;ffi;;;;;, hereina.fter carledl the 




*ha counitteo Ehall1 when'8o 'relltl€sted w a I'{'embor
relatlng to the lmplementation of Articlos 101 20
with Artlcles 16-21'







and 33r in accordanoe
Arll.cle:l5' : '
r.wrol.[emberstatewblohhaqlssleclamarkotlneaufborizatlon.fora
veterlnary medicinal produot shaLL rne*tt to the comnc{ttee 
a {'ossier 'con-







ot].rcn }.{enhcr-: $tat os g I
The committoe shalr- forthwith trtrreult ths,dbB*r.€r.r tc& thpaoepttent
authorities of thc spe6tftad:ldesrha.h Sta,tAgr{r.
$nch toaaorJ'astcae'slall be domecl to be'ery{rttdtrbnFtortho Brrbission bf an .opplioationrfor'narlrettngrauthorJ,rctf.on to'the. m,t,d.autlrbnitios,M..thin tdre
noanfuig of A:rtiolo 4r
ArticLc 17
I. ffr within a perlod. of j.2O days af,tor tbe clate of g16n$ntssrtot1".Seferne6 :to in Article 16 (2), no objection has:beerr:,r.rot:l.fibd to-the eorins"ttee by the
conpetent authorities of the Mcmber states specified,, the committee shalL
forrnally record the fa,ct and, forthwlth inform the Mornber statos conoerned.
2" where a Member state considors that it is unable to authorize thc markcting
of the vcterinarxr med'icinal product, it shall forntrard its Xrgggaiid{ objcction,
foundcd,. ia Articlo:.lg,ntthtn tho,sa^irl,lpbrl,od, of IAO dalrsr
Article 18
r. rn the cascs refc:rred to in article LT Q\ the committee shaLl consid,er the
matter and' shall d'elivet'ite'roaponecl,-oplnton withln-60 dF{rB firo.:r.t$e,.
expiqf of, thc timc 1init 1ald down Ln Articl.e U.
..2. fhc opinion of thc comadtteo shall creal wlth the
mecLicinar' prod.uct wlth the cond.itions sct out rn
compliance of the veterinar5r
ArttcLe L0.
Th': Committee ehall forthwith inform tire irfrember States concerned. of its
opinion or, in the svent of cllssenston, of tho opiaions of its mcmbcrs.
3' The ldember statqs concerned. ehall roach a decision on the applioation for
mankoting authorl,zation not late*.than lO days af,ter the rlate on which tha
inforroatlon prorrid.sil for i,n artlcre r? (r.) or parag? api' 2 -fierosf




r. rr soveral appLioatioos havo beca arrtr:r't$d' ln'aooosrlsna€. 'irlth 
at'ttole
' for marlceting autborlzation foF ttrp €aae voterinary 
mecl:Lcinal
produotl and onc ol morc' I{ember Statos has gfanted'Euoh authortzatlon 
shi'lo
one or nore of the other l{ember Statcs have refirsod' ltl.o": of 
t'he I'fember
Statesconcenredmaybrln8thematterboforethoConrmlttee.
the game sha1l apply whcro one or moro l{enbor $tates have 
suspendlccl or
tti,drherwn:rnarketlxSauthorizatlonwhilcorxeoSof.:thoother$enberEt*teE
have not d'ono soo
z. ttrs conunittee shall oonsr.tter the natter and sbarl 
dletri*" ilts'o*a'6orred'' oplrdon
{*ttl"Cs Xrht .}efs at tbe lateeta
3.ThoopinionoftheCornmitteephallonlyd.oalwiththeground.so:rwhioh










$he Committee sbnl!' set ertln6 'I*mif fo:r *l*f,ros?t'
particu.l"a^rs relatlng to thc conii+vi'*ns Laid' down
obtained' ilr, t'rc mcarrtino by H.tirl. l' l-i-'"'..,s ;u:3 in
bavc author:"aod. tho vetorinagy aicole1;ral 
prorluct'
ella$iaatlon }o!t"the Daale of
ln Articl'es 1'01 :26 or 4O




The cornpetent authorities of llember $tates eballlrinspdgf,ib ei3ee-l&erorthe
' interests of the Comrrunity are involved.p refer the matter to the corumittee
- 
before reaohing a d.ecision on an application for marketing arthorlzationg
its suspension or rrritbdrnnalr
A{tiqr,e 32
.1. fhe Cgrnmission shall report tb the Council annuaLly on the operation of the
proced.ure laid d.own in this Cbapter and its effects on the d,evelotrxnent of
intra-Comrnunity trade. It shall nalce'ie'fi:rlrttteryffi.rteofrcsggrdtsd:.,.:
the entry into force of this Directive.
2r'fn tho light of e4porience the Commission shal1, not later than forrr yoarg
af,ter the erttry into force of this Directive, submit to the CounciL a
proposal containing appropriate measures loading -to-_ the abolition of
anJr remaining bamiers to the frse movcment of vcterinaqy rned.icinal products.
sttll in-eld.sfohbee 
,, r, ,i.
lbe Colncil Ehoitl ta#e e &al.elon on the Ccrrrleeioa proposal not later









eroAOom afo subJect to the holdlng of an authorization'
2. The provlsions concerning ma.nufacture ancl imports from thifd countrics
referred to in Chapter IV of the ssconcl Dlrective 15/3L9/WC sh;rltr o991yr
Article 24
Tbe competent authority of the l'{ember $tate concerncd shal1 enstlJ|e by mr:ano
of lnspoctionl that the Legal reguirements relating to vcterina':iy meelicinali
proclucts are ;comPlied' with' 
. :
Such inspections shall be oa*led' out by officials reproUenirns. the oornpetpnt
authority who ahall'lro'Wueerod to t 
.. ;
nrrfqn*rrrins o:3 oor*ut"iul cstabllEhnents and anJr l'aboratories1. : Inepcct manufactrri:rg r c
" 
"rr*lrlil;-; ths holder of ths authorraation 
reforrecl to rn A:r{;iole e: (1)
wlth tho task of carrying out checks pursuant to Article 9 (2)ii
Iheo sanpLoe;
. .I!0an*na, anJi, documents rolatlng to the obJect of ths lnspeot:Lone subJeCt
to qu$ctrt,Frerri.tij"onE ' in the ltember $tates at the time of notifl'cation







I'Iernber States shall talce all appropriate neasures to ensure that the person
responsible for rnarketing a veterinary med.ioinal product and., where appropriate,
the hold.er of the authorization referred. to in.Article 23(1) nrrnrsrr proof
of the tests carried' out on the firrished. prod,uct and./or oa the conponents
and' internedlate produots of, the n:nufaotnrlng prooess, in accord.aloe r,rith
the methods laid d.own for the purposes of bart<eting authorization.
*rtidrJ-ze@
Tlre conpetent authorittes of tbc f{cnbcrrBtata+aha&I;,renspenr}rorqt*fr6rupioarlceting
authorization when it is cLear that!
1. the rneclicinal product rnay be harmful irncter the conditions of ,rse stated at
the tirne of applicatlQn for authorization or subsequently, or that the necl.i..
alna!, prod'uct lacks therapeutic effect or that its qualitative an4
qu.:ntitative eomposltion is not. as d.eoIared,l
2. the reoonnerded. .deila;n - r.. is.lnaclequate to ensur.e that food.stuffs
obtalnecl from the treated. anima,l d.o not contain resldues which night
endanger the health of the oonsuneri
3. the med'icinal produot is offered. for sale for a use whioh is prohibited.
by other Ooramunity provisions;
4. the infonnation given in the doseier pursuant to Artioles 4 and 1j is
lncorreot;
5. the togtE refemed. to ln article 25 have not been carried, out;
5. the obligatlons referred, to tn the eecond. para€rapb of Artlole 11 bage
not been fulfi1led..
.'
lbe therapeutic ef,feot is frtsslng when it ls established. that the roediclnal
' t'product cannot produce thereapeutic results in the epootes of antna!. fut',rh:ich
the treatment is intended.. :




the partisulare supporting the applioattont as providl'ect for i:n Artiol'e 4r
bave not been a,mended. in acoordanoe with the first and third' :paragfaphs of
Article 13;
.. anJr new lnforna,tion referred to in the seaond' pPragfaph of lrtiole 13
has not been conmunioatecl to the competent authoritiesr
Artt-l].e 
,2J
1. sotwlthstancltng the prorrieions of artiole 26, M'enber stat€s Ehall" take
,,..a11 neoesgary neasureB'to ensule that supply of the veterlnar;p neclioinal





b, the nedlolnal produot troolcgrtherapauttoroffootronrtbe-npecteg:of ' aninel f,or
whloh the treatnent was intcndetll
o. the qualitatl.ve ancl quantitative oonposltlon of, the nedlcinal produot
is not as d'eolarodL;
d.. the reaonnerded &l"y'-' ' ie irradeqtrate to enmre tba't foodstrrffs
.obtainecl fron the treatecl a.ninal d.o not aontai.n"reeidues'rllhlch'night
ernclanger the healtb of, the oonsuJn€r;
€r the tests referrecl to in artiole 25 have not been oarried' out or where
another requlrenent or obligation relating to the grant of' th1
totho"ization roferred' to'in Srticle 23(f ) bas not 'been coroplted'
n/
with.
2. tt!}1e oonpetent authoiity may oonfine its ord'er prohiblti'rlg sppply a'nd
' 
- 
ths withd.rawal fron the market solely to marrufactrrring batohes






1. the conpetent authority of a l{erober Stc:te shal1 su.spend. orwithdrawrtfte
authorizatiol. referrcd to in Article 23 for a category of prepar'&tions or
for all preperrations when one of the requiremente }aid d.oun for the
obtcining of this authorizationr ts no longcr ne*.
2. The corrpetent outhority of a Mersber Statc nay, in addition to the
measu"es set out in A::ticLe 27t cither sgspcnd. marrufacture or
inpurts of veterina,ry firodicir:al produots fror,r third cou:rtries or
suspend or ntthd;a'* .*te ar1**:rrlqize,t*hn:'r'cf,4;'r€c1 to an-ArLicle 23 for a
.category of'preparatrons or. for aLl preparations in the event of ncnr
'observance of the prcvlsions rega,rd.ing mcnufacture or imports frpm
r, third. ooturtries. '
*s$*s*39
}{ember States shall taice all appropriate neasores to er}sure that the cornpetent
authorities ccnoerned connunioate to eac,h other such info::mation as is appropriate
to seogre oonpliasoe rrith the regulrements for the a',,r-tborization refcrred. to
in Articlc a3 (1) or fornarl:eting c.uthorization'
4sjjslL3g
Al1 decisions taken prrr:ua3t tc ArticLes 10, 26 ard. 27, a1J. negatirre decisions
taken pursrra;rt to Articles 9{11) anrh:i8(.}1'uf'l *his Di.t',;r:tivo aad';i.l, dccld*cns to
wj-,thhoLd.,authooriaati-on to r:anir,:.faoture, ollto'.inporrt f:'m"t:l1:{drb**.rrti-'los or to
suspend or liLthd:f,,1w, .rranufacturing authorLza*ian shaiL state in detail - the
reasons on wh'ioh they are baeed.. $uch deoisions shall be notifj'ed. to the
party oonoerned. who shall at the sane time be informed. of the remed'ies
avai1abLe to hin under oql?bnt lrygi*b'?.atton antl the' tine*].lnit wlthin which
such ::e;tedies nust.be soughtg
Authortzations to place veterinarXr medioinal productson the narket and
decisions to revol"(e euch au+horCaattons, shaLl bo.tr&'Lished.'by'e'd,ah:IdenboflState




Oecisions to grant authorization to roarket, withhold, sosprBng or $grtfid!,alr
authorizationr to prohibit supply, to withdraw a tr)roduot from thr; narket
or to suspend. manufaotr:re or inports frora thirrl cou:etrLes of veterinar;r
nedioinaL products ehall ohly be. takan on the grounds set out in this
Direotive.
Arti.cle 32ffi
Each Mem'ber $tate shall,take all .' appropriate neasures to easure that
decisio:ts authorizing marketing, tef\r$lng or r4rlthdl€rrtng a, narlc6tlng authoslaation,
cAnoelling a deoisiorr reftistng or wlthcXrolrtng:!a$EetlAg.,ssnl66ahtl,on, p1r6htbtting
, t zupp]-y or wlthdrawing a product frorn the r,arket, together wilih thc treasons
on which such deoiEtons are basedl. 
""" 






Inbelline and rracl:ase inserts
in the PackaflinA of veterinar;r
-- 
#--.E..c*---
nedi clni:} p:,'oclact s
*-**:/i.F+*_+:--*
Article 33ffi
[he following particq.lars shc,l]. appea,r in leg:ible charapters dn'oontairrers
and orter packages of mcd.icinal proCuctsr
1. lTa^ne of thc nedicinal product, which nay bo a trivial nanle er a oogncon rrame
r^rith or r.;ithout a trade marlr or nane of the roanufaoturer or a soientific
name or foruula with or withort a trade marlc or^Rarne of the nanufa.cturer.
2. Ne:rt to the narne of the medicinal productrits gualitative arid qusntitative
oomposition erq>ressed in active conponents per d.ose*unit or as a peroentage,
aocord.ing to thc pharraaceutical forn and, in ad.d.ition ln the caaes-,?efewsfL
to in the soconcl pamgtq,ptr; of rlr.tLole 1t the ttacereqlstaacosr
"[he inicrnetional nqn-proprie]qf o?o?o recorilxend.ed by the World llealth
Orga^riization sha,1l be used, wherever they exist.
3' Reference nurober for production id.entification (nanufacturerrs batoh
nur'.ber),g
4.. Nunber of thc authorization for placlpgi tho trotorlnarTr.r:rcdlciyt*J produot on
the narl.iet,
5. I{ar:'e or corporate na^ne anO- p'ernarrent ac-l.dress or hcadrqr1g,rttiie. of -the pcrEon
rdsponsibtre for , 
.rtaci.ng tho rle teninary ncd.ial,nalL ilrocluc"b on the .narlret -aJxd,
t+fickr'apptr:ieab1by of, the r,ranufacturer a].so. , *
i'
6. T?re apeotcs of antr:al 'for c,hloh thc. nocllc:tnal'procluot ls i:rte$d.ccl, 1 .firo,ne*hoil
anrd. nsEuls of ad.ministrntion.












b{,L,d,qrn in the first paragraph of Article 11, if,
11. f}re words ilFor veteninarSr usetr.
the pharnaoeuttoal. form and. the contents by welght, voluare
nunber of d.ose.,{rnits need. only be shol,m on the outer package 
.
[he provisions of the
"tktnext Part 1, 4 to 0olrnoll DJrectlv.e of........rrrreorl the appro:rination of
the Laws of Menber states relating to a"nalytioal, pharnaoo-torioo.LogloaL and.
clinloal standard's and' protoools ln :respeot of the testing of veterttr'ry
nediiinar produots in eo,fh^r ae they coaoern the acfino i:onpononts of rreter{nar:r
ned'ici'rra^1 plroducts closct'lbed,"gualitatlvely and. $rantitati.vely eha..Ll epBly to theparticul.are gf.ven 1n polnt 2r ;,lrtic_Ie j4
As regard.s antpoules, the partiorla.rs, listed, ln
f,lttcl"e 33 she,LL be given on the outer package
however, only the following partiarla*s elra,ll.
the first paragraphr of
. Or the aatual c,ontainersr
be neocssartrrj
- 
r?ang of the med"ioinaL produot, :
- 
quantity of aotive substances,
rf,lo&ll€ of ad.ninistration
+ ref,erence nunber for produotion identifioation













As regarrLs narootics, in adC.ition to the particulars raentioned. in /lrticle
33, both the outer packago and. the container shal1 beir3 a speoial sign
oonsisting of a d.ouble red" lr.ne. 
,
Axgi*-.lz
l{trere there is"no outer paoknge, all the partiouLars wtrioh shoulcl feature




Ttre particulars nentioned. in itenrs 6r?1819, 10 a3d 11 of the first para!1aph
of Article 33 and in the 3rd. and 6th ind.ents of .Artlcle 34 sh:1-1 appear
on the,outcr paokage and. on tbe container of uredicinal products in the
lapguage . or 1c'ngr.ra,ges of the corrntrY in whioh f,hey'a,ro boing
plaoed. on the rnaJket.
i,tntiole 39
Meraber States shaLl tCce ali. arppr'opriete neasures to ensrre that tho paclcago
insert rftich rnrst be i+ol.uded in the packe,ge'cflb,veterinary ned-ioina'I
product relartes so1e3-y to that ned'icinal'pro'ductr ;
The pacl<age i.nsert rshalL contaLn :orrly tbe fol"lowing particulars, r^rhich
shall confouriwitlr the f:rfornc,tion.a:ad. docunents providedl purs'rant to '
,lrtioLe,4 and,r,rhi.ch have:'been approved,'bS the bompeterit duthorities:
llrtiele 35
single'dose containersr other than a.ripoulest
g"ive the particuLars nentioned. in llrticle 34t
33 shaLL s,pply ,onLy to the outer paoke"ge'
..r/or.
-35-
a.) IT,xtre or oorpofate na.ne and. perhanent ad.dress otr hosclqtrartorg of the person .
rospoBsibLe f,or plaotrg the rretor"tnary'nedtoinal product ort 
'bhe nosltst ancllwherrn
applioable, of the rranufaoturer aleo 1 ' L
t) Name of the ned.foinal product and. a statement of its adtive oonpoaont$
expressed, qualitatively and guantitatively.
Ttre inter:{a,tional non{troprtetary names reoomnended, by the Wor1d Healtb
Organiaatlon eha1l be used. wherever they exist. :
c) fte main therapstltio lndLloattoanl u contra-ind.ioatlons and. siile..offects
I'n eo f,ar aB thcre pant$eutrare &ro nccoesa4r for tho wo of tiho ne&tcl,nal.
proflnctE | . :
d.) [he speules of, i{.trlnat fbi*'whtch the'inediolnri,|l, pmodluct 'in interrrd.ed., the cl.oea,ge
stritabl'e fon' thtd speoLes, thb nethocl and r:eang of'edrxtralstr,retton andt.odvice
on conr€ot adninistration, lf neoeesary;
e) tf neoessarlr, all detatls oonoerning'the d.el.ay g
f) SpeoLal storage precautions, lf necessary;
g) rhe particulars required. by the first pa^ragraph of Ar.ticle 11, if
neccss€|rlr.
Artiqk_ 40.
!{here the provisions of this Ctrapter are not obssnred. and, er foroal notioe
add.ressed. to the person concerrred has bcon inO*poCtlve, tho oortrxltent
authorities of the }lember $tates roa,Jr suspend. or rrlthclmw'tho aufiror{.aatton to
place *be veterinary nedicinal produot on the narket.,
All d'ecisi,ons takon by vlrtue of the preoed.ing paragraph sha1l st;ate in d.etail
the reasons ori rqhich they are baied.. li deetslon sha1l'bE notffierd, ;to the party
ooncemedr 4long wlth the tenscli.os avbltao*le to hin umbr orlll,r,ent legC.sLation






1hn reqn:ircncats of !.fenbcr"sta'ice^{romccryreng conflitiofis otr supply to thc trru'bliot
the narking of prices on ned.icinal produots for veterinary use end
inC.ustrial property rights shall not be affeoted by the provisions of this
Chapter.








Menber $tates shal} bring into foroe the lawsn rogulati'ons a^nd ad.niniBtrattv'e
provisions ucocssartr to conpi-y with this Directive wi*hin eighteen
months of its notification a.nd. shal-I forthr'rith inform the Comnrission thereof.
l[enber Staies shall ensure that the main provisions of naJiona]. Law t*hioh
they a.dopt in the fietrd. governecl by this Directive cro conmunicated to
the Comnission.
Ar.t*c,te.$._
1, As regrar.ds the aHthorizations referrecl to in Article 23 whioh are issued
before the expiry of the tine*limit laic1 d.o'.nr in .Article {.2, i{enber
States sba}l grafft a.:r ac]dltional pedod. of one Jrcar to the 'uld-er'talcings
concerned to ene,ble then to cor:ply with the piovieions of Chapter V.
2. fhe other provlsions of this Directive shal1 be applied progressivelyl
within fifteen yea,rs of the notification referred. to in /\rticLe 42t to





3" Menber Stetos shall notify the Coremts$l.on, within three years follor,ring ;
the notification of this Dlrestive, of tho nrlnber of votcrina^qy iired.ioine,I
proc1uctseovered'byparagtraPh4a:rd,ineao}rzubqequentyoar'ofthe,
nnmber of '$rah products. for l:fuich the marlceting authoriaatlon referred
to in llrtioLe 3 has not yet boen issued,
Article 44




PROPOSAT TQR A COU{CIL DIAESTIVE
01[ THE APPROXIi,TATIOiT OF TITE LAWS OF I,TM.BER STAfES
RELAT n:TG ?0 AIIAI,13 ICAL r PIIAR1\IAC0-8OXICOIrOGICAL A:dD
crjlsxogt .- sstrEulnaBi aaD )pR0f0c0li8::







Ae with proprieta'ry ned.icinal products fol bunan beingsr it is necessarSr | ,,
in the case of veterinaly ned.ioinat produ,ote, to nake oertain ad.ditione to
tbe principles lald. dowr by the baslc Direotlve in ord.er to a1lon veterinary t
neclioinal produots freedon of novrnentr By deftning the dLata to be suppLied,
conoentlng tbe charaoteriEtics of nefioinal produatsl by setting out a
oolmon pLan for tbe preeentation of, these d.ata and, by layirag d,ornr the broa.d
linsa for testing roeillcinal products; thle Directive 1ril.1, at one and the
eaxne tiner assist narrufacturElg1 ootrp€tent national atrtlrorltieg and.the
0onrnittee on veterinargr med.ioinal products enviaaged. in tbe Counoil
Directive ...o.rr...r of ...r...r on the approximation of the lawg of
trfenber states relating to veterinary nredicinal productsp
fhis proposal tlas d.ranr Lp on ihe basis of the stuctieE road,e in the fie].d of
Siroprietary medlicinal. prbduots fon use in bunan bein_gs. Howeverr. tbe
special Froblenrs raieeat by veterlnary ned,islnal projoots have led. to a cen-
taln number of original pnovieions being nad.e.
rn tbe flrst place, it is inportant to protect the bealth of peopi[e rho
consuae antnal prodtrcta. Advanoecl phanraao-toxloologlcal studies bave been
plannecl in order to d,etermine tbe possible presenoe of residuee irr fooit-
atuffs obtained' from treatecl aniraals and. the effects of such reeldues.
fhese tests snrst nalce lt possible to establish tbe necessarlr naiti,ng peri.od
frora the tirne when the med.j cinal product is adtrninietered. to tbe anlnal
tutiL foocLstuffs are obtained. fron the aninalr in ord.er to e!.inineute hgnan
health haze-rds" It is aJso furportant, ho',levgr, to oonsicl,er tbe proteotion
of the treated- enimal; since, after a11., this iE the prinne objeot of, veterinary
ned'icinal products; but this gives rise to a itifficrrlt gtres.tion, i,.e. the
extent of tbe asstrxramoes rvbi.oh the corapetent authorities nay require as to
tle safety of the proiluct for the int*r,icd specles of apinal. In tbe case
of, neclicfual prod,rrcts for h',rnan use the enrJl,rer ie obvioue _ 6very pogsibl.e
agsufanog is required.. l,Ihere veterinarX. rneil.iclnal producte are cor,ce:rred,
the anewer iE not ao €6sf,r
./.
-2-
Fbon the scientific standpoint it is clea.r tbat all the to:dcity tests
(single dose toxicity tests, repeatect d.ose toxicity tests and tolerance
teets) must be ca.rried out in everXr case. 3y rneans of the first t;rye of
feet it is possible to determine whetber the proftrat is highly or fairly
toxio and gene:ral.ly to d.escribe the aoute sJnnptons of intoxioation. Tbe
second. t3pe of test provicLes infomution conceltring the r*echanien of, the
intoxioation process arxd. maJte it possible to id.entify th,e siC.e-effeots
which are nasked ln the aorte toxicity tests. Similar}yl the tolerance
tests in tbe intend.eil speoies of aniraal enab].e the ma:cirnrn tolerateil. dose
and. the intoLeranoe symptons to be egta,bligbed..
Fron the eeononic standpoint one mtrst neverthelesg consider whether all tbeEe
teete to eafeguardl the health of, the treateil aniraaL wil.l exoessively penalize
veterinary ned.icinal produots as ogainst meiLicinal products fo:r hrrman use.
hl tbe cage of veterinary med.icinal prodrretsl the toricity tests are
numerousi one range of tests is i$tendod, to protect the treated aninral,rs
bealth, another ran€e is iJxtended. to proteot the oonsrrraer of aniroal proctucts
(resi'ttue tegts). 0t* nuet theref,ore prevent the oost burden i.nposed. on veter-
i.nary regea.:rch fron hand.icapping the sal.eE pr.ospects of guch ne*icinal
procluots too heavily anrt thue fostering iltegal clealings in this rnarket,
which uoulcL nur ,oortnter to the airos pureued..
A aonrpronise solution is therefore propoeed: it ls clesirable that all the
tests f,or toricity bo oaniedl-out; ,riwerlbelesej,-ii '-r;";'i;, .rt.r..'. ..: o-..,i ' .1
oonnid.ering in peurtisular the ilireotions for the use of the necLicinal proiluctl;
the inveetigdtor na6r subnoit reasons for not carryi:ag out the repeated dose
toricity tests; these l.Eatons rll.l of, 6ou$Bs te apprataed. by the conpetent




fI{E COI]ifCIt OF T}E N'ROPEAII CO},$IU1XIIIES,
Ilaving regard' to the Treaty esta,blisbing the Elropean llconomic Cormrrnityl r
and, in par"tlcular rirtisle l0O thereofl
Il,aving regard. to the proposal. fron the Commission,
Irtrcreag the approxi:natlon begun by Cou: oil Directive ......,rr. of ...,.....
on the approximation of tbe larrs of the idember states relatlng to veterinar;r
raecLi.clnal producte ehould. be oonti-nued and, the lmpleroentation of, .bhe principles
laid. cl.orur in that Directive ehouLd, be eneured,;
Hbereag a&ong exlsting d'ieparities thoEe netatlng to the control of veterinarSt
neclicinal procluots are of fturd,a,nental lnportanoe and, polnt lO of lihe.eecond paaa.*glaph of,'Artlclo 4 of the eald bireotive requires that appLicationE f,or
authorisation to plaoe a veterlnary nefieinal, product on the narket ehould,
be acconpanieil by particulars and. d,oouroents relating to tho resu].ts of
tdsts and' tr-r-als ca^rriecl out on the product concerreedll
Wbereas gtand'azds and protocole fol the performano€ of, tests and, t;rials on
veterinarSr nedioinal proctuots are an effective ne ng of oontrol of. these
pr,utlucts and' bence of protecting publio healtb anrl oan facilitate tbe mov€r-
nnent of these producte by laying d.olsr rrnifora mlee applicable to teetg
antt trials and. the oonpllation of dossiers;
llhereas the adoption of tbe same standa,rd,s and. protogols by al1 the lderaber
Statee wiLl enable the conpetent authoritles to arrive at their decislous
on the basis of unlforn tests and, by reference to wriforn criteria and, will
therefole beLp to obviate diff,erences i.n etaluation;
,/,
*4-
Whereas the ptrysioo-sSsnirall biological or micrsbiological tests proviil.ecl
for in ponr:,t lo'pf ttrs goconrl ,parr,grarir of Ar*icll' 4t tbo salel Biroctiyc
a,rc oloscly rclated.' to psints 3, 4, 6 and. I of the 6ai,d,
paragraph and it is therefor€ neoessarXr to epecify the d.ata to be provitLed,
uncler tbcse polnts 3 :
l'lhereas the r,raiting periocl refelred. to i:r potnt'8 of ths sscorrl garagSadt of the
B&td, A#n,cls 4 nust be deterrdnoi! in
accordance with the rezults of the tests and. trials provided. for in point 10
thcreof 3
l{hereas the conoepts of barnfirlness and. therapeutic efficacy refened. to in
Article 1.0 otr the aaC.d Dbect*.ve. ear, on1-y bc.
exa,rnined. in rela,tion to eaoh other i::r1 l:arre only a reLative significance
cl.epend.ing on the progreeE of goientifj c knowled.ge ancL the use for ;.rhich the
ned.icinal product is intencl.ed.; wher,c.rs tir.e particulars and. d.oo,,:m^.nts which
mlst aiiconpany an application for: aui.h,:r::-2,;:,tion to place a vefe::rnr,.r]r rnedi-
cinzu, 1r:"uduct on the narket nust dernci:;b:i,ir,i;e that potential haza':'ui; are
outw'::ir,hi,d by'rhe therapeutic effi-cac,' o:l-ihe produ,ct; r.rhereas rtraii-ing such
d,erao:rsf;r:ition, the application nust be rcjected.;
lrlhereas it is the guality of the tests and. trials which i" p"*-"*inent; where-
as i;he iests and triale canied. out pursrrant to these provisions must there-
fore 'i;e tuken into oonsideration i.ruespeci;ive of the nationalfty of the
experi;s who perforn then and the cor.rntry trhere tbey are carried out;
Wherea,s technical progre€s requlree fapidl adJu9lneat cf tho prorisione of the
;llnrryx to -thiB DLrectivol #rysgas;to nalco, it easler to adapt to, tbe ne&Fures
,,{.1
requiredl for this prrrpose, p- n ' : .: ghould. b€ a prooedure to engr.re
olose oooperation between the Henber S*ates ancl. the Conraission within the
Stand,ing Comnittee'on lded.icinal Proctuctss





l4rember $tates sha,Il take all appropriate neasureE to enEurel tbat
the particulars mil d.ocu.nente which must acoonpanJr applications for authoria-
ation to place a veterinarXr ned.icinal product on the narket pursuernt to
points 31 41 6, 8, 9 and 10 of the sqoord ga,nagt4aph.;.of,:arrti.ole 4 of the 0ornor.l
Directive 
... ... f . . of 
." ., ... .. r r olr tbe approximation of the l,a,tm of
Ifenber States rr]ating to veterinarXr meiticinel products are submitteil
by the persons concerned, in accord.ance with the Annex to this Dirrrotive.
Wrere, under point lo(a) or (t) of tbs ssoond;patagroph ef, Artlol,o 4
of the gaid Direo*ivep, lef,etsnoqs 
.to. prrbll"glred data, ars
eubnitteal, tbe provisions of this Direotive sball apply ln like nannero
Art_iglg,-a
, *e arnendnents neoeEsar1r for ad.apting the requirenentg of, the llnnex
to this Directive to technical progross shaL} be ad,opted in aooordemce with
the prooedure laicl d.or,n in tl,rtleio l(:l) ana (6) {ae'anond,od.) bf the oounoil Dlrectine
Iof .oo(cn!urr. rolating to anal;4ieal, phoruaco-toxicological, and. cli.rrioal
9tand.'rdE anil protocol.s in respeot of the testin6 of proi:rietary ned.ioi-nal
producte,
The Committee'irefemect to in 4*tiotre 3 {epr.Fnerxled.) of the aaicL
nirestive may examine any question relating to the application of.bhis
Ilireclirri: whi*h io brought up by its Ohairnan, either on his oun initiative
or at the request of the nepreEentative of a Monber state.
A:yticle 1
Ilember States shalt put into force .She lamn regnlattoas ranl, adnlnlstlatllr€
prori*lo:ro ulod?d. {.n olden to ecrp3.y rrtth ih!.s Mrooti.vo wlthin 18 nonths of lts
not!.f,icsr.iicn anAr Bhell for*"brrlth infonr the Oonnleeion thaneofo
Memb.er States shall enEure that
the text of the main provisions of natlonal law wbioh they adopt irr the
fielit covered by thie Directive sre oorenrurioated, to the Cor.rnisel,on,r
ArLlsle.Jt






aslusel*effircq* ITEI{ICAL, BIOIOGICAI OR MICROBIOLOGICAT) '1lFT5 OFEr&.c-4r:_ BsF-c*.a *s-eer---r."-.E-
Et; $'*.*,d^il{iil;'ili*** *p., i;i! g
A. Qualitative and. quantita.tive particuLa,re of the connonantgG---
The particulars and doouments ilhiah rnuet aocomBanJr applicationa f,or
narketing authoriaationgprrrsrrant to Artiole 4r point 3r s€oond. parag*aphp of,
Counoil Sirgctive r.r.r..rrr.rf...... of.r.!..rrr.r..rr on thg app,roximation
of the laws of rldenber States relating to veterinarXr ned.ioina^l products sbal.l
be subnitted in acoordance with the f,olloning reguirernenta r
l. nsra.litattve partioula,rstr of atl the conponents of the midioiaa"l




the cernponant(s) of the e.xoipients, whatever their naturs or the
qua,ntitl,' u*ed, inolud,ing ocl.ouring agont , g:rurr. i&,ir.Iser etabilizerel
th:"c,":errers, enu.lsiflersl anti.-s.g'g"tuti.nl*ir:.g agenls, flauouring ard
41*1s,1i; i; sr:rbat*rx$,lep gaa p,rcp,i,l.l&ni:;s 1 €tcr r r r
, i oor.rp,,vi;snfs of tiie phr.,rnnc,.;ut:cr,i fcrm (e.gr caFBLl€, caohet) intended.
to be lngeotad. or otlrenrise ad.iirinis'berecl to animels.
Tbeee particulars ehall be supplemented by a^ny relevEnt dleta ootlcerniug
the oqntainar and, where ap:)t.or3riatel tho way of oloeirrg itr
2, flhe 'tusual tenninolog/ttr to be usecl in rtegcribing the oornBonenta of
me-diainel pr.r-rdrrctnl nerx.*rwi.thout pr-ej."ul.ice to the appl,ica'licn of the
other proi'ioi.oria of Artiole {, pcict Jr of the saict Direrrttve t
- 
cotnpuleoriLyl ln respect of eubstanoee whioh appear ln th'e f,\rropean
Pharmaoopoeia or1 fait ing thi.s, in the nationaS. pharmacopooia of one
of tha,tienbe:r $tatesr tha p;'5ncipal cLesigna'iicn uEed. in the relovant
monograph, with refereirce ta the pharmacopoeia conoernedS
./.
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in respco-b cf oth,er substaneos, the inte:rrationar non-proprietary
nane, recor"anend.ed, by tlHCl which raay be aeconrpaniod. by ar:-,ther non*
propri-etarxr naner. or, failing these, the oxact scientific. d.esignation;
substa,nces not having an intersrational non-proprj-c.ba,r;- :r$:e or 4n
exact scientifio designation shaLl be described. by a statenent of
hovr and. frora r*hat they wer.e prepared.n supplenented, where appropriate,
alr;' othel reievant d.etails;
- 
in rcslect of coJ-ouring agents, d.esi$nation by f,hs rrrirrr cod.e assigned.
to there in a f\.r.ture corrvroil Direative on the appro:<ine:tion of the
rtrles of the.i',lenben $tates concerning the colouring agents authorizod.
for use in proprietary med.icinal products, ,
3. In orcler to give 
"quantitative particulars of al1 the components of
the med-icinal- productrt it is necesearXr, depend.ing on the pharnaceuticaL forrc
concen:ed't to specify in regard to the aotive substar:ce(s) tne weiglrt or the
number:of international units, either per dosage-u:rit or per u:rit of reight
or volume and. i,n regard. to the components of the excipient, the peight or
the rtolune of eaoh of them, with due allowance for the d.etails provid.ed. in
section 3 belor,r.
This infonnation shalL be suppleraented:
- 
in respect of parenteraL preparations, by the r,reight of each aotive
substence in the writ contaiirer, taki^ng into account the usable volurne
of thc proCuct;
- 
in respect of neci.ioinal products to be aiLninisteierl in d.rops, by
the wcight of each active su.bstance containcd. in the number of d.rops
correspond"ing to an average d.ose;
- 
in rcspeot of sJnrupsr eisulsionsl granules and. other phar,i-aaceutical
forrrs to be adrninistered. in measured. quantiticsr bJ, the weigbt of
each active substanue per measured- qualtity.
..
Active substances present i:r the forrn of conpounCs or d.erlvati.ves shal1
be desoribed. mrantitatively by their total weightr and if necessary or relevast,
by the weight of the active moiety or raoieties of the nolecule (in the case
of chl-orarnphenicol palmitate, for ex.,rcple, the weight of the ester and. that
of the co*esponcli"*g chloranrphenicol shaLr be given).
-9-
The-biologroal units of aoti.vity of proiucts which ha.Vo nol; been
ilefined chernioallyr md on which there is insufficient bibliographical in-
formation, shall be e:cpressecl. in such a wa;r as to provld.c unanbigtrous info$-
naiior on ';irc acth"it;' of the substs,nce, e.g. by statfuig the physilological
effect on lftich tl:e nethod. of iletcn:rini:rg the c].ose is' based.
B. lss*si.st i og-fl[-$93}o:*-g.f--r*Ra#+n
' fhe "brief description of the mothcd. of preparation:f acoonpanying the
applioatlbn for rnarlteti-:rg authorization pursuant to Article 4r sereon&.garagraph,
. poi.at, {g-of,--SonrrciL Directivg .r.rr..r..}r.. of, .r.'..}'.., slra}l be drrafbed
in such o. tr*oy as to give an ad.egrrate id.ea of the nature of tho opere*ions
enployed..
For this purpose it shail inslud.e at least:
- 
nention of the various stages of ne,nufacturer so that an assessnent can
be nad.e of whether the processes crnplo;rsfl in producing the pha^rrnaceutical
fo:m night have brought about an adverse change in thc componenl:s5
- 
in the case of a oontinuous proeess, f\rlI d.etails concerrring precautions
tal:en to cnsure the honogeneity of the final product;
* the.actual manufactur:i.ng fornnrlal with the guantitative particrtr.Lars of
all the substances used, the que.ntities of excipients'1 honcvef, being
given in approlinate terms in so fa:r as the phar.roaceutical form rnakes
thl.s reqessary; nention shall be macle of Ar,r"v substances that raa;1 didappear
in the course of nanufacturei
-,a sriator,rent of tle sta.ges of manufaoture at .which Bampling is carrieil. out
for insprocess control tests, pherg g-ther d.a'ta iin the d.ocunente supporbing'
the appLication show such tests to be neceesarTr for quality conibroL of the
med.icinal product. 1 .l
. /.'
-lC-
- :li 'li; rf b-sic substencee
For tho purposes of this parag?aph, trbasic substanoes".shall me..m all
the conponents of the medicinal product and., if neces$arjr, of its contaiilerr
as referrerL to in paragraph il, point l1 above,
The particulars and d.ocrjr;ients l..fuich nust aeconpany the appLication
for marlleting a.uthorization pursuent to Artiole {, second. paragraph, points
9 and 10t of Cowrcil Direotive r.....r.fr of.rrr.rr.. sha,ll incluCe the
i"esuits of the tests relating to g,rality contro} of atl the components used.
fhese particulars and. docrxtents sha1l be subnitted. in accorda,::ce with the
followin6 provisions. .
r. P**-s}&glllsgeJigi q{ ig-A*q.Intr"wg}.4s.
The monographs of the ,-Errropea.n Phar:raacopoeia shalt be applicable to




respect of oiher substances, each l{ember ,$tate rnr,y require obsenrance
national phar-:aoopeia with regard. to prodr:cts nanufactured in its
Conponents t\rlfilling the requipernents of the Lbropean Phannacopoeia
or the pharnacopoeia of one of the iiernber. States shall be d.eemed to cornply
sufficiently with Article {, seoond. paragraph, point 9, of Gorurcil Directive
r..r.1i|.r.r of .ri....or.r,.. In this co.sc1 the d.escription of the aflalytical
methotls nay !s rcplacecl by a d.etailed. referenoe to the pha,rtacopoeia i-n
guestion,
. $eference to any of the pharrnacopoeias of ::on i,{erater countries may
be pernittod. in cases where tho substance is d.escribed neither in the
Europea.lr Pharnacopoeia nor in the national ph.arnaeopoeia concerrned.S ,j.n tha*
case the norograph shall be submitteC, accompanieC lrhere necessary by a
translation for wlrioh. the applicarrt shall bc res.'orarrihtir-
-11 -
Coloruring a6ents shaL11 in alL caseirr'' sritl&lf;1 tlre'lbqu,fie..rcnts'rf
a ftrture Cormcil Di:rective on tho approxi.nation of tho lal"rs of the .lienber
States ocnoerning the colouring agunts'authorizecl for use in proprietary
re4iciuel lrroclucts.
For routine tests on eaoh batch of basic substanoe, onl-y that par*
of the pha"nnacopoeia reLating to verification teets (p'rrity and str,en€ths)
shall be nand.atory; the firLl range of, id.entity tests need. not necesrsarilJr
be perforned. whe:re those that have beln perforroeC permit an r:nambig*ous
characterization. In this oase, the reference to the inonograph of t.he pharrna-
ootrioeia nentionod. a,bove shalL include details relating to. this aspect.
2. Basiq substances not in a oharrnaoopoeia
Cornponents which are not given in any pharnr4copoeia shal]. be ilescrlbed.
intheformofa'monographuna"rthefc1lowrngbead'ings:
(") Th,q-nary-glq_qhgs}b$tF{rs,er meeting the reguirenents of parag:raph Ag
point 21 shal1 be supplemented. by any trad.e or ecientific strmonynsi
(f) ?pp, Le5q,f.+pti_q+ of*tbgjjilgt,e+99, set il,orur ir:. a for:n sinilar to that
used, in a 4escriptive item in the European Fharmacopoeia, sha1l be_ accornpa,nied.
by an5'necebsary explanatory evidencer especiall.y conoenring tlu rnolecular
strrrcture whore appropriatel it rnrstl in such a case, be acco:':rpanie,l by a
brief ind.ication of the methoil of slmthetic prbparation. I.lhere subs'bances
..r .-.t,{ .-)r ;.:.
can only be d,escribed by their nethod of preparation, the d.esoripti,cn wilL
have to be sufficiently iletailed. to charactcrize a substimce which is
constarrt both in its composition ancl in ite effects;
(") lkliroFs. ot i-4ggli,fiqgrtf o" nay be d.ivid-ed into comi:l-ete techn:iques as
rrsed for the formulation of the rned.icinal productr arld tests tftich oug[t to
be oarriecl out as a routine rnattern
,/.
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(d) efilf-lgggg ehaLl be clescribed i.n relation to the sur* total of
pred.ictable impu:'itiess especially those which nay have a harnf\rl effectl
andr' if necesssry., those nhinh, having regard" to tbe neCicinaL associ"atlon
to whlch the application refers, inight adversely affect. the stability of
ttre med.icinal product or d.istorb analybicaL results.
(u) !lr"e gssav ;bsgh3iruq(sl nust be clescribeil. i:r sufficiently precise
d'etail so as to be reproducible in checklng tests canj.eci out at the leErest
of the con'rpetent outborityt any specia.l appa,matus and. equipnent rnrbich nay be
usecL shal-l be d.escribed. in ailequate d.etai1, possibly accoupanied by a
diagrarn. The fornulae of the Laboratory reagpnts shalL be supplemented,, if
neoessa,tryl by the method. of preparation.
The stand,arC il.eviation pf the nethod., its rcliability ancl tbe accept-
ability licrits of the results shall" be speotfied, and., if necesaaryl jus*ifiecl
in the light of feasibility and the prog?ess of scientific lo:owled.ge.
I^Iith r6garrL to comprex substences of plant or animar origin, a
clistinction must be mad.e between the ease where multiple pharmacologioal ,.
effects render a ohemical, physical or biological checlc of the principal
components necessaryr afrd the case of substanoes containing one or nore
8?oups of principles exerting sinilar actionl in respect of whioh an pverall
metbod of d.ete:rmination may be accepted..
(f) 4S\r'.,ipegial elgo$gipps, that ltav be Jrecgssary dlqiJre Stg,{EgeJas}the
basic substance ancl, if necessaryl its pto*,peg* ].i,f,q shatr be given.
-\-Q}g-€s, Outtula manuf 
"cturg-
fhe particul.ars and d.ocr:raents which mrst accoropany a:r application for
marketing authorizationl pursuant to Article 41 seoond, para€raphr points 9
anil' !.0, of CounciL Directiv@ rooro....rrf.. of o..rr...rr..r shalL more
:..
es$eciall;' includ.e parbiculars relating to tho product checks that noay be
oarried. out at an internetliate stage of tbe narrufacturing process, with a




TheEe tests are eesenttit'to ver.i'fy the eonforrnity df thd rned-loinal
prottuct with 'bhe fornrula nhenr'exceptionallyl an applioant proposes an
analytical technique for testing the finishd'd. pr^odrrot which d.oee not lnclud.e
tbe assay cf alL the active stbstances (or'of, aLL the cornpbnents of the
exoipient subject to the saine requirenrents ad the active substanoes).
The sar,re applies where quality control of the finished. prorhrct d.epends
64 fulr.process cbecicsl parbicularly if the roed.icinal product is eslrehtially
ilefined by its method.'of preparation.
D. Chacks on the finished. prcduct
Tbe partiouLarg and. d.ocuraents which mrst acoompany the ication
foi mdrketing authorizati.bii prtrsuant to Ar-tic1e {.s seoond. p points
9 ancl 10, of 0orrlcil Directive oo......'. of .'..'.rrrrrrr;.8
particulars relating to cheoke on the finished. product. They






etics o icaL f
cbecks on the general oharacteristias of a proiluct whlch can:,in the oourbelof the riranufactuiing prooess shall bia inoLudetl
on tbe finished. produot. 'i '
As in guid.eline, and.'subject to the requi**"tt"'of the'I:,\rrt5pean
Pharuadopoeia or the national phdnrraoopoeias of i[ember Statesl thr: general
characterietics which afe to be verified for various pharmaceuticrel forrns
are given a;b point ! below. '' ' r' '
' [hese oheclrs shai]., wherever appLi.cablo1 relate tcj^the ver:Lfication
of arrera6e woights and rraxi'$trm'deviations, to mechanlcaL, physiodl or
microbiological t.es?s', o*,lanoleptic characteristics such ai clarity, oolour
and taster and physical oharabterist'ics sricb as d.ensityr pIIr ref,rjeot'ive-
ind.ex, etc. For each of these characteristioo, standnrd.s and- linits"*;i "' '
be speciftetl by the'applicant in eaob' particrilar ce€rer
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2. Identiflcallgn anLaseay ofjrgFilg ggEstanZe( s)
fhe descripti.on of the tochniq'ues fo:r analysing tbe finished. product
shall- set out, i:r such precise d"etail that they can be reproduced. read.ily,
the nrcthods used. for iC.entifieation and assay of the active substance(s)
either in a reprcsentative avera€c saripLe frora the production batch or in a
nurnber of d"osa4e-rrnits consid.ered. ind.ividualLy,
In every ca.ser the rnethoils ntust correspond to the state of scientific
pr"ogress at the tirne arid. give detaiLs and explanations concenring the stancLard.
cLeviations, the reliability of the ar:al;rtical nethod. a.nci tho naximum accept-
able deviations.
fn certain exeeptionel oases of particularly cornplex mi:ctures, where
tbe assay of active eubstances which are either verJ,'numerous or present in
very snalL anoru:ts would. neoessitate an intricate investigation d.ifficuLt
to camy out in respect of each marrufacturing batchp the assay of on1 or
nore aotj-ve substanoes in the finished. product nay be onitteC., on the express
cond.ition the* such assays are rnacle at intermecliate stc4r:s in the production
plocess; this rela-*-ation may not be ertend.ecl to. cover the charactenization
of the suhsterrces concemed.. This simplified technique shall then be s,upple-
rnented by a method. of cp:antitative evalua"tionl enabling the competend authori-
ty to have the cohformity of tbe med.icinaL prod'rot with its fonm:lla verified
after it has been placed on the market.
In ass*y of bidLogical activity shall be cbl-iEf.tory uhcn physico*
chemical methocls carrrot provid.e ad.egr.rate information on the q;ality of, the
product,
llhere the particulars given in parag apb B show that a slgnifioant
overa€e of an actj-*e substar,rce was enployed. in the rranufacture of the
ned"icinal procluotl the desrription of the method.s'fsr.checi;ing the finished
product shall inc1ud.e, where eppropriato, the chernical ancl evcn the toxico-
pharrnacological investigation of the ehanges that tb,is substance has irnder-




. ' ..- 




3. Ia_eglitiqati_o-4 q-44 assay of co 
-eIgi€j€glp
An upper-limit test shall be rna,:rC.atory in respect of exc:lpient oompo-
nenbs which'are subject to nrles rolatin6 to toxic substances or which aro t
useci as preservatives; furthermore, components liable to affect :physiol.ogical
functions shall be subjected to an assary'
The meihod. proposed for id.entifying colouring a4ents must enable a
verification t'o be made that such agents appear in the list to b,a append.ed
to.a future Council Directive on. the approximation of the laws o:fl the Ivlember
States ocncerning the colouring agents authorized for use in pro'prietary
med.icinal produots.
In so far ae ie necsssaxTr, the components of the excipient ehall be
subjected. at least to characterization tests. '
4. Safety tosts
Apar! from the toxico-pharmacological tests submit.ted. with the appli-
cation for marlqe'bing authorization, particr:Iars of 
.safety tests (abno:rrnal
toxicity) or ,local tolera^nce in animals shall be incluclcd. in thc analytica.l
dossier whorover suoh tests must be und"ertaken as a matter of ro'ntine in
order to verify the quality of the nred.icinal product, : ..
5" General charactertstics of med.iclnal products to be verified systematicallv,
depend.ing on bhe t:hamaceutical form of each product
The fcllowi-ng requirements aro given for guid.ance and. without pr+-
jud.ice to any requir_ements of the l$uropea& Pharmacopoeia or national
pha:rmacopoeias of ldember States; for example, mlcrobiologicaL testing of
preparations to be ingested. oraL\r shall bo performecL in accord.ance with
the requirements of the Europcan Pharmacopoeia.
- 3*ES!*-egg-.glJ.lg: colour, weight and. occeptable varlations in unit weighi;
if necessarTrr d"isintegration time with tho method. used to d.etermine this.
- lggl3E-t4lglg,t coLour, d,isintegration time lrith the method. used to d.etermine
this; weiSht of finished. tablet; weight of cone and, acceptable variations




tine with the method. used. to d.etenjrlnettbis;
contdiit i i^rittr a.oiEptable avariafibnd' in ririit
gg: oolour, d.isintegration
appearanco and. weight of
'weigbt. -
- &t'sLs:gp,*ss,.g4ps.rgtlw.:Jlsl$s"uher! g4l-os.ff1,gltr,g*q?p.elll99r-
€f.+iiijl::*: in e,rLciition to 'rhe requir,enerr*s of the parbi-ouLe,r pbanraceuticaL
fori:r, resjstance time in aa a:rtificial gastric fluid., with the rneth-rd used.
to deternine thie; clisintegration tine in an artifioial intestinal fluid.l
with the nethod used, to d.ete:rnine thie.
EeP3R*,lggs*sjL$SgleL*lg*sS9ige*c-9e&irlsll*Is jsL*sr.a_sgg_EsJ!.
ggl*;.,:;:9.;'g:,lill{er., 
.;i.'.-.},i3,J,,'l.: in ad.dition to the reqrriremente peouliar
to each phe'rmaceutical form, verification of the effeciivencaE of the
ooating fo:r the d.esired. puripose.
in ad.dition
to the reguirenents peouliar to eaoh phe:maceutical forr:n, requir+nnents
relating to grad::al rel-easel with the nethod, used. to d.eterroine this.
-.9ach*-Er Pa*<elq a.rrd sacbets: nature and. weight of, contente anil acceptable
variatioris in uid.t r,rciAht,
- Fafel]ter4 prepBfations-: colourl vclune of contents and aoceptabl.e variatioas
in this volu:rei PIlr clarity of solutes, size limit of particulate matterj'n the case of suspensions; sterility tests, with cl,escription of test
raethocls ancl, if necesser]rr B pyrogen test with cl,eecription of rnethod..
*gpgg+9$-Iglh FJI+ gontenl: Er.antity of nedicinal product per anpoule anct
pemitted. variations in weight; sterility reguirements and testg,
- 
Orinkable aropoules: oolour, appearance, volume of'content and. acceptable
var:iations.
gotr$rt ffiq Eqr.ffiigten€SI ns*ebt aad EEaep,}*[Ie
sss€emJ Sf {i6#.**"ttss}t q#i-tw,S pf SS.B+g*p?ri *F S,SS,*q'S ,g_$..-q.S.$,* S&e.r.p:},J,s*,g8d,o.d.testB.
- &UlsigpFr colourl type; stability.





colours wglght ancl acoeptable varia'tions
or clisintegpation tirnep and. clescription
&"oS"*ir1 clescriptioll of container qrcl
particl'e size*Limit r where the product
'tfuere e'finiehect pruduct ie
proituote the applicant snret r'eport
assay nrethod.s.
int
iny'u:rit r*eight ; raelting teilperature
of the urethocll
valve with d.etails/of outPut;
is intendecL to be inhaledl'.
sheLf
Euc3xgnp@*r-SXg-tg$i."*g.: ootrou$; eppear{xroe1'6terilit$
tes'us, with description of, the roetbod u*ed.; nhere'a'Spgop*{&de1 ol'arity and'
size*Iirnit of, particulate nat*er i$ the easd bf'grff$rsnpieets; plH dteter'rnlnation'
:,.
Strmrpe. solutes, etc.: colourp appearance
Pre-rnix foruulations f,o-r-qgdicgLq{lgeecls: iB edd.iticp to the reqltireueatF
G|.-els*.#r--.:=z'.ffi
pe6i'Liar to eaeh irharnaceutioa]. forsr 611 usdfirl" info1lfhqi't-O6'dn''the' ' "
cbaracteristles of the pre.+ix fclsulatlon .epablirrg a etfiiclentny bo48-
eous rucdi.oafe.A f,oEd, to be r.rqnrefu
* Pf,cpanations for q|4iq!St-q?139!i' is :* . .€.+ss.H arS,{*e'RG #,--t tffi? hsggge.,gJ.l3**.B'l9sI*t41*lt eoleu'i$r
Cojl-1.;:'"ii:j'ncy-g te:"glrt of content illel; iA the cas'e'Of, prodUots presr:nte$'1r*
singr-t rlo$-sbloqse ds6a' fo*rE1'a't$cnsr r{s&btr'e weid6 ld't'P *rceptrlb'l$ .'
deviaiiorre etsdi,{ltty tefrf n $$ dptorrnsvra#tbn'
'r. S&cihlli*Y*ie*e !
'ffUe pa,l"t$outafg and doeunertts tdh$,d& iln.l"st g,cosftpasf-'the lt$plisa{if,oJi f;ati
Ul+efu*tnuU .alrthciri.zatidn pur:Euant tb ;&rt'$"cLe i{, pecond per66raphr 'Fointu i6
,e&d. 9r gf Uouhqt!, Dtf.eCt'tv€ trirr*r.rr.r'i*,, df r-.n.rtt*s'' ehaltr 'be Slrbinitte&'
ia acoorde,lrce wtth the foll'otlifig requiremeiito.
A dleachtptlon ehall te 
€flva of tbe inwgtisatldns by nhich the
-life propoeed bS tho applloant bae teen tetersined''
,:.,..,-
Iiable to give rise to torclc d'egradatlon
these avrct iadicate charaoteriz;ation or
, j,Iy' l






l' stucfur of the interaction between the medicinal product a.rrd. the
container shau be subnnitted. rsherever the risk of such interaction is
r'egarded' as poesiblel. espeoial!.y where parenterar preparations or aerosorsfor intgmal we are ooncerned.
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Part 2
The partiaulars and. ctos.mentg tltrich nust acoonpriny the appl'ication
for rnarlceting authorization pursuant to article 4t .second paragrapht
pOint J.0, Of COrrfrCiL DireCtiVe....trrrtrr of rr;t"t"rrm BhalL be aUbmitted'





1. the potential, toxioity of the rned.icinal procluct and' any d'angerous or
unilesirable toxic effetts that na,y oQour und.er the proposecl' corrd'itions
of rrse in e,:ninalsi tlrese effetts should be evaluated' in relation to the
gravity of the pathologieal concl'itj'on ooncerned;
2. its pharrnacolog:ical propeftiesr fu both grraLitative and' qtranti'bative
relationship to the proposed' uEe in aninalsi
3. to what extent ancl for how l.ong after use of this med'ioinal pnochrct ln
anirnale there exiet residuee in food. products obtaincd' fron the aniroalsr
what are tbeir possible ha.rrrfirl eff,eote on I'Ian and what are thelr draw'
badcs for the inctustrial prooessi:rg of food'
AL1 results rnust be reli,able andl of general applicabiLity. whenever
appropriatel nathematicaL arrct. statietical prooedrrres shalL be uged' ln uoplcing
out tbe e:cperi.nrental methodg anil in evaluating the results. trbrth'ermoret it
is necessary for clinicians to be glven inforraation about the the'rapeutio





$ingle-dose toxicity test means a qualitative and. guantitative studgr
of the toric reactions whicb nay rcsult fron a si:rgle adrninistration of the
aotive substances contained in the nedicinal produot, .in the proporbions in
which they are present in tbe actual medioinal product,.
:
t{herever praoticable, the product in its actual pharuaceuti'oal forn
ebal"l be eubjected to a,rr a.cute toxicity test,
Ihe single-d'ose toxicity test loust be camied out in at 1east two
nanmalian speaies of tqown strain, and at least two differcnt routes of
ad'ninietration shall nornally be used." T?re sturly rith troo na.uinaLian speciee
,oq:r be replaced by etu4y with one ma^rnnalia.n speeies an6 ar: azrimal speoies
of another class for whioh the ned.icinal protluct is intenderi.. One of the
forms of adninistration nlust be id.entical with or sinilar to that proposed
for use in the animal for whioh the roecticinaS. product ie intsncled. andl. the
other rnust be a route ensuring systernic absorption of the pr"oiluct. The stud.'i,
mrst be oarried. out on equal nunbers of male and fenare aniraals.
tbis study r^rill d.esoribe the s;nmptorne olsewed, inolud.ing local
reactione. I'lhere possible, the tD, value with its confid.ence limits (gS {r'l
will be noted. the. period during nbiob the teet aninals are observed. shall
be fixed. by the i"nvestigator and shall not be less than one week.
r:a the case of aotive eubstances in a,ssociation, the study nust;:be
camied' out in such a way as to check whetber or not potentiation pbenornena
or new toxio effeots oocur.
2. 4gpeateil-dose toxicity
Itepestcd-dose toxicity tests are intend.ed. to reveal any phsrsio1ogical
and'r/or morbid' anatomical ohanges induced. by repeated. a&ninistration of the
acti've substai?ce or association of aotive substanoes und,er examination, and.
to deternlne how such changBs are related to dosa6e,
.1.
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generaL1tr,1 it ia desirable to perform at least one tegt the dturaticn
of whiah shalL clepenct on the conditions of, clilical use; its purpoce Ehall
be to cleterninc by experirnent the non-toxia dose rangp'{f tloe"pioduot
eXa.oinecl during the trial.. fhu investiS-ator nust give reasons. for tbe extent
and. dwatlon of the trials and the dosages ohosen"
If, boweverl baving rega"rd. in partioular to the d.irections for use
of the nedioinal produotl the reeponsible investigator see8 f,it rr'ot to
aaflTr out this exa,rninatioh he mrst give ad.eguate reasons for bis dpcision.
Bepeated-dloee toxicity tests nust be cariect out on two species of
narnnalE one of which muet be E rron-tod.entr Wher€ver it is feasiblel the
Etudy uith tr,p nrynmalian species sha.l} be replacett by a stucly wil;b one
species agd, alother anirnal species for whioh the necl'lcina1 procluot is in-
tencled.. The choice of the route(a) of ailrninlstration rmrst depend' on thoee
envisa6ect for therapeutic we ancl on tbe possibilities of syotemiLc absorption'
The nethod. andL frequenoy of afuainistration and the length of the triale
shall be oIearIY stated'.
Tha naxgun cloee shoul,it be chosen, so as to bring harrofirl ef,fectg
to ligbt. Sbe lower dloses will, then enable tbe aninalts toLeranc'E of the
new proiluct to be d.eternined.
The evaluation of the toxie effects shall be basedl on obsbnration of,
behaviour' growthl blood, pioture an{ phpiol,oglcal testsr espeaially tbos€
relating to the excretory organa, end, algo on autopey repo:rts and aocorapanying
histological d.ata. The ohoioe and rsnge of, eaoh gf,oup of tests t{ill depend'
on the species of anirual usert and the etate of saientlfio laaowleit€p at the
tine.
t
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In the'oase of new conbinetions of lm,or.nl substances that have been
investlga"ted in accord-a^nce wlth the provisiong of this Directive, the
long-1g3t tests n:ay, except where acute and. subacute toxiolty tests have
deaonstnated potentiation or novel toric effeots, be sultably nodified. by
tho invostlgator who shall zubnit his reasons for^ such nodificationsr
$ubstantrcs that have been shown to be safe by wid.e usagg., over at least
three xee.rs in cl.inlsar'treatraent of human beings, and by the resuLt of
control I':d' trials shall be treated. in the Bane way as lxeowl substences whtch
have already been investigated. in aocordance rndth these stand,ards and
protocols.
4e '*g'rf nieet r'ei'ad' f,or the ftrst ti.,ne. *n'tbs pbnrtdroottf,oel fieldt, sbsll be
treeted like an aot:Lve ingredientr
l. lg_1gXen.$jg-I["-:Jr-eglpd_speglers gf alringl
This study nust be camied. out witb all aninal speoies fon which the
ned.ioinal prod.uct is intended. rts purpcse is to carry out in all the
animal sPeqies for whioh the rnedicinal prod,uct is intend.ed. looaL and.
general tolerance assa.ys to .estabiish the naxirnun does tolerated. and the
clinicar slrnptoms of intolefance using the reoomnend.ed. route or routes, in so far as
,/.
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it ie possibl.e to attairr tbis aira by .lncrea.cing tlre therapeutic d-c,se. Itre
report on the trials nust contain ag many iletaile as possible on t;he expeoted'
pharrraoologioal effects and. the adverse eid.e-effeots; the lrtter ntust be
assessed. with due regaril to the fact that the experinental.anirnalsl may be
of very high va.luc.
The rnedioinal product shall be adniaistsred via the routes likoLy to
produce the appearance of the pharmacological effects .sought. '
. Where the trials mrst
the sequential raothocl roay be
be carrieit out with aninaLs of high unit price
uged.
llhis nethod. oonsists in calculating e, non-lethal theoreticrrl dose'for
the aninal oonoerled on the basis of the pharmacologioally effective
d.oses d.oternined. during the experine4tal triaLs with the n'edicinal
procluctl bearing in mincl the uraxiraum tolerated doseg obserued' d.trring
the Eingle*close toxioity stud.yl in accordance with point 3.1. This
d.oee thell.tfueaibq"-9Cri:i,':riuto#5*.to an animal whiah ehall be watohecl
velXf carefullSf in ord.er to obtai-tr as rmrch inforn'ation as possible
regarding the effects of tbe nedicinal product. If the animal presents
no s3nnptons of intolerance the test shall be reconnencecl with another
animaL using a higher d.oee the stren{1bh of which shall be left to the
investigatcrts cLiscretion. If the aninral eaeil.y tolerates thie nelr
cLose the test shall be continlr:cl with a yet higher close' The d.ose
which rm:st not be exceed.ed. l,rj.Li be founcl when synptoroE of to:cicity
o.DpeeJr If the animal dies, t?r': test shal} be reoornnenced wlth a
lowe:l d.ose and so onr In evei^/ r:ase the airn is to deternin.e a single
cloaage which enables a favo'...rtii1e pharmacologioal ef,f,ect to be obtainedl
without harrning the anirnal.
Any exoipient ernp}oyecl for the first time in the pharmaaeuttiaaL field'





This stud,y oonslsts in exa^nir:ing the tcxid anii abcrtifaci-ent ef:lccts
observed. tn the proflenJr when the med.icinal procrrct wrd.er rnvcsti.gation is
also intend.ed. to be a,lministereC. to the female rluring pre3natlcy, The tests
in guesticn may bs carried. out as parrt of the c1i:rical trials.
5. -lxaninatio:r of reproductive f\rnotionE--.@
If the results of the cl-inical trj-als reveal a^n;"thing suggesting
inpairment of male cr fenale reproducti're fLrnction or hermful effects on
progenyr the reproductive fr:nction 
.rmrst be invegtigateJ. by appropriate
test s.




. Pharnacocl.ncamics neans the Study of the variations csused.
ned.icinal procluct in the functicns of the organisrn, irrespective
these fbnctions are nornal or experinentally ncd.ified..
by the
whether
:i . This s'budy rmrst follow two distinct lj-:res of approach,
Fi.rstl the actions on ruhich the recomaenCod. application in practice
is based shalL be ac'Lequately cLescribscl. The results shall bc e,ipresseC in
quantitative terms (d.ose*effect curvesl time-effect curves ctc.) amcl,
wherever possi.blci to comparieon witir a product whose activity is well
knor,m. Ir{here a higher therapeut:.c.cocfficient is claineC, for a productr
the d.ifference shaLl be Cenonst;rated. by reference tc the oonfid"enpe limi.ts.
Sccond.Lyr the. i.ievestigator shaLl- give a general pherraacologioal
asssssment of the subsr;ance1 referring in particular *o the possi.bi.lity
of sicle-effects. Tn generaly tbe main functions of the pbysiolcgical
s3rstens shoul4 be rnvestigatocL; the rncre closely the d.oses liab1e to produce
siile effects rpproxi:nate to those produoing the tlierapeutic effects for which
the product is being proposed., the nore thorough this investigation rnust be.
i
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The experimental techniques, unless they are stande:ld proeredu;res,
mrst be d.escribed in such d.etail a"g to al"Iow then to bo :reproducecl, arrd
tle investi;ai;or rmrst establish their heunistic vaLue. The 
.oxrperinental
reeults shatl be sot out clearly and. for cetrtain types of tests their :
statistical si€irifioanee shall bo quotecl.
Unless good. reasons are given to the contraryl argr guc;ttitative
nod.ification of effects resulting fron re$eated adninistnation of the ilories
shall also be investigatecl,
l,[edioi.nal agsociations nay rssult either fron pharmacological pronrisses
or from clinical indioations. In the first oas6, the pha^rmacodgmaruic study
sbal1 deraonstr,te thoee interactions whtotl nrigiht raake the association itself
reoomnendable in olinicaL use. In the second. case, whene soientif,ic justi-
fioation for the medicinaL association is sough"b through clinical experirnent-
ationr the investigati.on nust d.ete:mine whetber the effeots expected, fron
the association can be demonstrated in a;ri;nals, and. at least the inportanoe
of any sids-effects shall be lnvestigatecl. If ari aseociatlon incl.ud.ee a
new active substancer tho Latter rmrst prevlously have.been studic,ll. in d.epth.
a
2. PJrarmapoEinFtics
Pharmacokinetios means the study of the fate:oi nred.ici.:ea1. iproducts
within tbe crganisr,r, and, oovetrs the study of the abeorption, d.ist:nibution,
biotransfornation (or netaboJ.ism) and er.iiaination of the proausts,,
The stuCov of these .clifferent phaseg'.nay be ciarried. out by inoans 'of
physicall chemioe.l 
.or biological metbod.s anil. by obsenration of thrj abtuaL
pharmacofimamic activity of the rapdlfa*ae.
Deta oonoerning d.istribution and elimination shall be nece$sary in
respeot of chenctherapeutio products (antibiotice, etc.) *a prodrrcts whose
use d'epends on their non-phaflaac.cdynffiric eff,ectsr ,'and tn etl oas6$ where
such d.ata are indispensabLe to d.eternine the dloeage for aninoalg.
./.
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In tbe ca^so of now associations of lvlotlte rsubstataes t"rhich have been
investigatecl in accord.ance with the prcvisions of this Direct:ver phartnae,r-
kinetic stud.ics shaltr nct be remiir.eil irf th: t::;lcit;'tc:ts r:ri el-i'-icil
trials jusiif;r tlrelr cnissioir. lhe ;eurc applies t.: subst:xiccs tlurt have
been sh:r^m to be effective and. safe by vory wid.e usage over a period- of at
leaSt three'Jtears in hrl'rap or aninial therapln ancL by cln'brc1led. trials.
res i c]:cs)r<lwwff-rl
Fcr the irnplenentation of th:-s }ireotive ffresi'darc st shall rnean alL
active ingred.iends or rnetabolites thereof which remain in raeats 
or other
fcodproduced.frontheanirnaltowhichthened"icinalproductinguestion




fron tieated aninals, and to ascertain the wai'ting period's 
'bo be adhered' -bo
in orcler to obviate any hazard to hur'ran health ari'f or any drawbacks 
for the
industriai Prooeesing of food'
Asgessnientofthehazard-duetoreslcrues*"!*:':.*"::l"t"ihgthe
presenceofresidues,if.arry,arrdtheinvestigationoftheeffectsofthese
renid-ues in the trgatnpnt of- 'aninals under nornal conditinns 
of use'




for the rersults of the pharmaookj-netic teets" At var'r1ing timcs a'fter 
the
test.and.nalhasreoeived.thefinalr}oseofthe'ned.icinalp:'ocuctthequantities
of rcsidues prcsel].t shaLl be d.etcrnrinec by appropriate physical' chemical
or biological rnethoc.s; the technical procedures and. the reliebilit:l 
and'
sensitivityoft}remethod'semployed-mustbespecified-,Theresultsmustbe
checkecL as far as prssibl'er 'iitr at tbe least' by sampling'' i:r the 
cick
animals for r';hich the medicina^l product is recoromenclert'
.1.
'; 25 ';
2.'Investiiation of the effects of resicuee
.'. Li-.i''. ",*---ir. l- --"th-\ t'''::i,cit:r.f oral.ly atlninistero4 resi*nes!'*..*. n'-*'-.--r{-.--*t".-...-,sa.e-+5.-dr,./.!rrgJ-+It.ffi..ah.ry.?,Ffifq+r+F-rr+
' [he stucly of the chronic (several nonthe) toxidity of orally ad*
mi:tistered resid.ucs shall be perforncd. clifferentl.y accbrding'bc whether it
is a nedlcinaL pr.oduot that is elininateC without tra:rsfornation or cne
that is neteholizecl. In the first case the researcber cln wcrlc directl3r
on the medicinal proiluct. In the second case be mrst nolh shi).arl.lr on the
principal metabolites which are for:nd chiefly in food.. If the mctabolites
cannot be isolated. or s;mtbesized., recor.rrse shall be hacl to tbe stu{y of
1Itrelagred. toxioitytt wtrlch consists of operatlng with tisEues irr which the
greatest guantity of residues ha"s bce:r traoed. or with products fr,rn treated.
animals.
The trial.s must be camied. outl using the oral route, in t''uo naromaLian
species one of whicf rnrst be non-rod.ent. 
.nn: 
usual duration of the trials
shall Ue 3 : 6 rnonths, ff one norks rl.irectly on the meclicinal prorluct or a
netaboliter the d.oses must be fi:iecl with due regard. for, the rcsicitres actually
present anC. nust 'be selected {n such a m:y that the highest d.rse (Jelses
harsrfuL effects to appe.ar as far as i:ossiblep while the l'rncr clcsos then
enable the linrit of toler::nce in aninals to be fcr.md.. If the stud;p of
rrrelayed. toxlcityil is ad.optedr the upward. gradation of the closeg :Ls linited
by the quantity of reEiduas.aotually present,
The evCur,'bicn of the to:iic effeots shall oe based. on oirservati:n cf
behi;viourn grcutLr blccd picturo encl physioLogical tests, espocialily those
relating to the exoretory orgdursr and also on autopsy reporbs and acconpanying
histological cla*a. The choioe ancl range of eaoh group of tests wi1.l d.epenrL














Tests to reveal ca."cinogenic effects are ind.ispensable:
in respect of substenues hrjrla;a cJ"osc cLienicar an:;log;r r.rith l:r:,r,n:
cerci':rogenic or cocarcinogcnic coi:rpounC.s l
in respect cf substarcs,thich have 6iven rise to suspi-c.ious changes tluri-ng
the repee.tcd.-C.ose toxicity stuel.
Tests to revea,{ fie:ratogenic effects are ind.ispensa.blel
tr. in respect of sfi*$Ws bq:rlnsnQlose 
"h**ioalt'**o* with iarormteratogenic procluotu p
2" in respect ofsrrb.ste$resr,ftich have given rise to erspieiouo.p!.,en6pe dnnirae the s';r:'
' of effects or the reproduotive ftrnctio:rs.
The stud; of teratogrenic effec'ls shall be carricci out with at 1east
two animal species: a bree.d, of rabbit sensitivc to knctrn teratcgenic substances,
alrd rats or nice (specifying thc strain)" The details cf thc test (number of
animalsl alounts administered. and cr:teria for evaluatio.: of rcsults) shall
d'erend- on the sta'bc of scientific ]mowledg'e at the tirne wlien the a.pplication
is loi""ged-, anC the level of statis'tic:L1 significance tl:a'b the results must
attain.
trlFthcrmore, the stud.y of mutagenic effects a-rri- allcrgic phenornena
is also rd.esira.ble.
Tests on the orig'inatfon of pesisti*rt pat]rogenic germs arc necessarTr
in the case of residues 1f the n:edicinal procluctg usel, tc prevent or treat
conta6:ious cliseeses in l,ian or atrrirrals"
\ *.c/ !ig-?gJg$"+ses fcr tle r+4rlE ar_p jg f.i ^n
fn pertain cases it r:ray be necessarXr to gar*;1 cut tests to cleterrnine
whether resiciues consti.tute clisadvEu?ta6es for tech:ological procedures in the
industrial pmccssi::g of ford..
-28-'
The stucl;r of the effocts of residues in accord.ance with points a)
' ';itc c) shall not bo reErireC if it has been cstablished. tha.t thc ned.ioinal
product hae been rapidly and. conplotely ellmlna"teil or. if it is only use'i.
ocoasionally" In such ca.E es the naiti.:cg period. shall be cLcternined. in such
a lray that mea,surc.ble residues are not includ.ed. in the food-.
E. i,Ied.icinal. nroil-usts for topicaL use#ffi.
ldherc a mcclioinal proiluot is tntend.ed. for topical uso, systenic i
absorption nust bo investigated in the intenCed. speci.es of, e;riroe.I. If it
is proved. tha.t s;rstemic absorption is negligible, the:repeated,*d.ose toxicity
testsrthe foetal toxici y teets and. the studies of reproductivo function
referred to at points B.2r 3.4 md 8.5 may be omitted.
If.the neclicinaL prc{uat is absorbed. systenrically in a significant
qrrantity lhcsr the standpoir:t of view of residues or fron that of pharmacg-
dgmanrics (concentration) or if such systemic absoqption hr,s to be expected.
in the case of accidental orai ingestion of tbe med.ioinal pro*uct by the
aninal, the rneclicinal product rnust bc investigatecl. in accord.ance with the
requirenents of points B to D.
In all cases, tests of l-ccal tolcrgnce after repe:.t:d. atlministration
shaLL be ce.rsied out and. shal1 incluC.e histoLcgioal exnninations. l,ilhere a
ned.ici.nal product which ie nct eystemically absorted. rray enter a food. prod-uct
obtained. frorn the treated. animal (roainmary implantsl etcr)r *+he asnay of
residues in accorcla:rae witb point 3 shall be oaried. out each"ti:ine.
Cha.pter 1I: Ptosentation of particulars and. riocunents
.T--:-:-
As i:r a;r;' soientific work, the d,ossier of toxicologlcal and. pharraa-
cologlaal tests shall incLud.e the fo1Lor'lingt
a) an intnoiluction tl,efining ttre subject, ro"ori*led. by anSr usef\rrt biblio,*




b) a cletailed. eqterinental protocol giving the reasons for e,ny omission of
certain tests Listed a,bovel a doscription of the methois, apparatus ancl
raatcria.ls uscii, letails of tirc spccicsl brcerl or stl.i,i'r ci r.-ri":r..1e,,
wbore thcy uerc ob'bained., their nru:rbcr arr.i. tlie conC.itj-ons uircrer which
they were iroused, ancl fecl, stating, 
-lgggg*3&ig, whether thcy were specific
pathogen-free (SPn) or not i
c) all the imi:ortant rgeults obtatne'd, r.rhether favour"able or unfavourabLe,
flre original data qhouLd. be described. i-n eufficient d,etail to all,ow the
results to be cri!ically evaLuated ind.epend.ently of their interpretation
by the author. r3y way of e.:planation and, illustration, tire results rnay
be acoompanied. by reproductions of tgnocgrams, phctonic::ographsl etc.g
cl') a statistical analysis of the reeultsi wtrere such is called. for by the
test properlrile, and varia:rce within the d.ata;
e) an objective cliscussion of the results obtai.:r:ed., leasing to ccnclusions
on the toxicoLoglcai and. pharniacological properties of th.e substance,
on its s::fety raa:'gins in the in-Lencied. aninal anC. its posslble sirl.e-effects,
cn its field.s of application, on its actj-r'e tl-ose levelr: a,nd. aty possible
inconpat ibilit ies ;
f) infcrnrc.tio:i showing r,rhether the conponents of the neclicinal prorluct are
usod. as neclicinal productq in hunran therapy; if thig is so, a, report
should be naCe on alL the effeqts obses.ved. (includ.ing sid"c-effects) in
i'{an and. on their causer where appropriate ir the liglit of trial results
or biblirgra.ihical d.ocumentsg wlere conponents of the ried.icinel prciuct
are thenseLves not useC as med.icinal ptoducis in hurae,n tirerapy the
reasoils s',rould. be stated.;
6) a" d.etailed. clescription encl a thorcugh d.iscussion of the rosuLts of tlro
study on the prcsence cf residues in foocl and. a:r assessnten-b of tire hazard.s
they consiitute for l,[an. Aocour:t shou].d. be taken of alL the factcrs which
may be of iral:ortance, particularl). with regarcl to custon:,ry d.iet and levels
of contamittation bJ'f,oreign natten present in the environment. In the
case of each reconoencled use, this d.csoription shall be foLLowel by pro-
posals concerning the waiting per:-ols vrhich, allow'ing for an adequate
,/,
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safety nergi::, inret be so eEtablisheri as to ensure the* no f\rrther
ree'i1uc rcnains *.*:U 
"ti l"t this is ir:rpossibl:r 
*:-ensurc -it:i- i
dangcr to .;m rs eliroinatgd. bii applying internationally rcoo63:,ia
assessrlent criteria (aose d.ovrl.l of effect in animale, eccepta,ble claily a
dose, saf,ety nargin of 1.: loo or </> I : 1tr0 accorcl.ing to a,vailabLe
information, etc. )1
h) alL 'inforraaticn necessary to aoguaint the clinioian as firlly eus poesible
' with the util,ity of the proposed- prcduct. {he discugsi,;n shall' be
suppleracnteil by suggebtions .]s to possible treatment fcr acut€, tcxic
ruu"iiorru in anina1e to which the product is to be acir,rinister€rd. anil^
for s{ile-effeots.






The particulars and Cocunents rvhich mrst acconpalq' application6 for
narketing authorizations purnaant to Article z.|, pcint lC, second paragraph;
of Council Dirootivg r?r..fr'rt... of r...r.r...... ghall be submitted. in
accorrdance uith the provisione of chapters r ancl. rr below.
g!gi*!f_l: Q.opdugt. gt,tT_ial$
The purpose of alinieal trials is to d.emonstrate or to asaertain the
tberapeutic ef,fect of the ne*ici:ral procluctl to specif} its indications and
contra-ind.icetions acoord.ing to species, its d.irections for use, any sid.e-
effects it na;' hatre a:rd. itE harrnlessness wrd.er nornaL conclitions of use.
CLinical trials rouet be preoed.ed. by acleq*ate ph.arniacological alad.
toxicity tests ca^zried, out in accordance with the provisions of this
Directive eincL1 rvhcre they are practicable, by tests oarrierl. out pref,erably
on the one or more animal species f,f,r which the ned.icina,l procluct is intenclect,
The investtga,tor uust acEraint himseLf with the concl.usions of these
prelininary trials.
I"s far es pcssible, olinical trialE nust be carried. out with control
aniraals (oontrolled. clinicaL trials)l if it ie econontically justifiable, the
theraper:.tic effect obta.ined. should be oonpared. both r.rith a placebo and with
abseree of treatment and./or with the effeot of a roeil.icinal product of heown
therapc"rtlc value that ha"s al::eady heen used.. All the rasults obtained.l
whether positive or negative, must be reported..
The nethod.s used. to nake the fiagnosi.s rtrst be specified.. The results
nust be set out by making usp of guarrtitative criteria or criteria represented.









Partictrlars concorning clinical trials nust be srr.fficiently d.etailed.
to enable an obJeotive judgenent to be nad.e.
1. r?,ecord.s of clinical obsenrations
rytr*+ CaCr*# S:5-:!;ary<*:F.**r* :F**
All the particul.a:.s nust be supplied by each of thc irwesti.gators on
incl.ividual reoord-.sheets of clinical obsertrations in the caso of oolJ.ective
treatilent.
fhe parficulars supplied, Ehall. be classified. as followEl
a) narne, aclclress, flrnction and.'wrlvorsity qualifications of investigator;
b).plac,e anC d-a'';c of 'r;:.ea*rnen*; nanie .r:r: arl,l.ress of ow.ler of i;.lre r-ni-rne-ls;
c)"'ir: t.ttr; cc,;:c of' .i.:r:,r.i-:. ir::r-l:iai, t:r:'',',at,i:e:i:',; i-::ri'l r:'.;,i.i e,l'l.l j.ye J;.i'ct,ij;r:,'t'i 1 : i. Lhe
lai."l l:r' ,.'.i:.r; :r, (-: {,,r;:. -;.:..'-',, jil.,.-:.i j.:f .i:iri j.r)t:i ,r..t.!l; ,;',;3.i,:';.'i11. i:::lr:ar,i.sr naIJeF
Ot. I,:ir;!.:i., C.t :1 .1",".','.. ,.,;i:r'.i. ^r.i, i';1r;r,.,r-i;; i):' : \;tliti:'t,i .ii'-)I '.,.ji):i.i;h.;:, nex
(ir: ,!l'.: :r.'-,. i I -- .1'.,-"t :', r. 1..;.lr r. i;:. i;i,.:':,1:r.r.rl FJ-.:il'ril::t ol it. rrrtih ai,nci, in.
. 
, the ,.;:r',:'i t,l"n,.rl.il:.',-.i.n ::-'. ,":..,i: 
-:,,r:,,l
d) nfeth:d .)f -,'i:)i:li:j.r;:,i 3i1.1 ll':::r.;1-::';,ir ,it;.li!r:g +,.1i:;1i3.1';3e an4" gUantity Of Anyi'
ad.i.i"i;it,'.;;" 
'-',..,: .!\, i:r-.:::i,.''--'. ...::. i'.i;..; f ,;.,,.1.'; .''
e) cai;e f-i: t.-.:'i,' (a: €-tl ri;r irr-:iir, l'.1..i...:); o*ci;l:.rcnoo e,nd. cortrse of any inter.r
, CUj]I',.'lf.t Il'15E,l-q11':1 
; 
'
+\ r; ., ,.... i .".^..- ..*.r '-- "..-r-^ .-L,r i/r s+r,,r'ir-r,.,,:.;,r il-:l 'i Ilii'&ili t;l.E :d" :;.1 t..::,I;C .1.-b I.
g) s;tipti,.rii:. ,.r.1?; sevebitSr,;f: -;hc :i.i,:,,rirs,:e i.f possihle giving criteria represenr
-;. tel!. ,;:: ;.1"r,1,r;,1":; ( ofosuel:., ,1.1 ,.1,, i ,
h) d.orag+. ot'-iJi,-,,llC.j.*iui',!. p::,lrc;, rnethod., route and freguency of aiL:ri.nistr*
tion r,';t 1 pr'i-rr;.::-i'i; j.':nR, -f,'l eir"!'r '-r;; n c'-::r.r-'16 administralio:., (cluraiion of
in; e" '. i ur-, , e'l c, ) ;




i) aII. details cor:cerning ned.icinal prodncts (cther than that being assayeil)
which havo bcen adninistereC Curing the period. of exanination, either
prior to or concurrently uith the test product and., in the latter case,
d.etails of the interacticns obser\red.i
k) all results of the clinj"oal trials (includ.ing unfavourable or negative
results) with a fuli. gtatement of the oli:rical obse::vations and the
results cf tho objectivo tests of activity (taboratcry analyses, physio-
logical tests), requirec to evrlu.ate the appricatio::; the techniEres
used roust be speoifierL, ancl the si,gnifioance of any varia.tions in the
results e4plained (fo:r exa$ple, variance in method., varia.rce between
inCivicluals or the effects of the rnedication)g dencustration of the
pharmacodynamic effeot in aninals siralL not alone suffice to justify
conclusions conccrning any therapeutio effect ;
1) all partioulars of the obge:sred. sid.e-offects, r.ftether hanaflrL cr notl
and of aixy:neasureg taken in conseguencei relation of cause a:rC. effect raust
be investigated. with the sarne care normally accorded to'iclentifying a
therapeutio effect;
m) effect on a:rimalsf perfornances (egg-1ayi.reg, nilb production ancl reproduc-
tive f\mction) i
n) arr opinion conoerning each tndividual case or, where several series of
collective trea,tment are concerned, an opinion on each coJ.lective c&s€r
Onission of one or more of itens a) to n) nuet be eq:Lained..
Lhenr in respeot of particular therapeutio indications, the applicant
can show that he is r:nable to provicLe cornprehensive d.ata on thorapeutic
effect because:
a) ttre ind.lcat ions for which tbe rned.ioinal proCuct in guestion is intend.ed.
are encountefed. so rarely that the applicent oannot reascn:.bLy be
erpectecl to provid.e conprehensive evid.ence;
b) in the prcsent state of scientifio larowledge, eomprehensive information
cannot be proviC.el,
-14-
rnariketing autborizatioa nay'bd granted subjejct to'the 'fol"lowtng conditions:
a) ttre nedloinal product ln queEtlon ghaLl be supplfed on vcterlrrary prescrip*
tion :nl1'a,rrd shall.' in certain'casesl be aclninisterecl only rrrrd.er strict
veterinary supervi$ion ;
t) tbe paclca69 insert ancL a,ny other i:rformation shalL dralr .the at;tention of
, the veterinery practitioner to thc f,aot thatl in certain speoi,fied respectsl
thg larticuLars available concerning the med.icinal prgcluct in Erestion
are as ;ret in:.clequate,
[]re person responsible for plaoing the veterinary rneclicine[ procluct
on the narket shall make aLl'necessary a,rrangenents to ensure the.t the
original docrxaentsl which formed. the basis of the data. supplied., are kbpt
for at least fivc yeare as firon the clatc of transnission of the d.ossier to
th.1 oornyetent authority. 
. , ,: .,, : ; .,
2. $llmelf,-,and coqql_gq dnsr#!-"'r::.
flhe c]-inical obsernrations referyed. to in para6raph I above sbaLl be
swrnarlzej. in a s;mopsis of, the trials and their.reeuLts, inclicatingl ". 
.
a) ttre nwrber of animals treated. either ind.ivirlually or colloctiv"fy, *itf, 
"
breakdom accord.ing to species, breed. or strainr ?g€ ancl sex;










reseiverl. another nred.ioinal procluct of





e) details ooncerning test anirnals which may be at increaser'L risk cwing to
their age, tlreir mod.e of rearing or feed.ingp or the purpose for lrhicb
they are iirtend.eCr or alimals -r'rhoce ph.r's1.tr*ioal or pa*Lrclcgical cond.ition
requires soeoiaL consi.leration;
f) a statistical evaluation of the resultss when this is entailed by the
prograrnruing cf the trials and. the variability of the fe,ctors involved*
Final}yn tho i;:vestigator shaLl draw gener"al colrclusions frcrn the
experircental. ovidencq, expressing his opi-nion on the heruXees&ess-cf the nqAioinr,.l
pfoduct, uncier ncrrnal coaditions of use, its therapeuiic effect arad a;:y use-
fu1 infornation relating to ind.ications and. contra,-ind.:cations, d.osage and
avera€e duration of treatnent and., where appropriate, any ia*eraotions
obsenred with other roeclicinaL produc-bs or feed. acld.itives as well as any




Lo Comit6 d.es rldd.icaments vdt6rinaires (ch. 1tr) est compos6 d.e repr'6sen-
ta.nts iles Etats inembres et d.e la Commission.
11 d.oit 
€mett:re un avis d.ans 3 cas !
- 
lcrs:pre le responsable de la mise sur le march6 grri a obtenu une
lbro autorisation nerticnale Ie clemande pour accdd.er i ! autres march6s
anr moins,
- 
Iorsque d.es d.dcisions nationales d.ivergentes sont prises pour un
m?me produit,
- 
lorsgtrtun Etat membre souhaite prend.re lravis du Comit6 avant de
sg prononcer sur une d,enande, une suspension ou ltn retrait dtautorisation.
2. Le nombre d.e rdunicng tte co Comitd est pr.u:ement conjecturol puisSrril
il6penct ]. Ia fois d.e la volont6 des fabricants et des Stats membrosi iI
est propos6 d.e le fixer d 12 par an. Chaque Sbat membre d.oit pouvoin
envoyer un maxinrum cle .| experts (un atlmlnistratif, un ana\rste, un toxi-
cclogue, un clinicien). Les ,experts gouvernementaux bdn€ficieront r$1ique-
ment du remboursement des frais d.e voyage.
J' Compte tenu du nombre des expert* (+ par Itat rnenrbro), les frais i pr6voir
pour la Commission st6lBver:orrt::ar r6union i Ia somrne cl.e 210.{00 I'B, soit
arrnuellenrent d la sorffqe d.e 230.400 x L2 * 2,?64.800 FB.
1.
